Page 5«..4567..1020..»

Archive for the ‘Bone Marrow Stem Cells’ Category

Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study | Blood Cancer Journal…

Preclinical evaluation of FasT CAR-T cellsFasT CAR-T (F-CAR-T) proliferation in vitro

To characterize the in vitro proliferative capacity of F-CAR-T cells, F-CAR-T and C-CAR-T cells were manufactured in parallel (Supplementary Methods, and Fig. S1) using T-cells from 6 B-ALL patients. To investigate the ex vivo proliferation of F-CAR-T, frozen CD19 F-CAR-T and C-CAR-T cells from each patient were thawed and stimulated with irradiated CD19-expressing K562 cells. The number of CD19-targeting CAR-T cells was then determined during the course of cell expansion in vitro. As shown in Fig. 1A, upon CD19 antigen stimulation, F-CAR-T proliferation was much more robust compared to C-CAR-T proliferation. On day 17 post co-culture, F-CAR-T expanded 1205.61226.3 fold (MeanSD), while C-CAR-T expanded only 116.437.2 fold (MeanSD), (p=0.001). To characterize the mechanism underlying the superior proliferative ability of F-CAR-T, we purified CD19+ CAR-T cells from both F-CAR-T and C-CAR-T. The expression of genes involved in cell proliferation, cell cycle, and apoptosis was analyzed using Nanostring (detailed gene sets are in Table S2). Gene expression profiles showed higher F-CAR-T expression scores for genes associated with cell cycle regulation (F-CAR-T vs. C-CAR-T, p<0.01) and lower expression scores for apoptosis-related genes (F-CAR-T vs. C-CAR-T, p<0.05) in F-CAR-T cells (Fig. S2A).

A Ex vivo cell proliferation of F-CAR-T and C-CAR-T derived from B-ALL patients (n=6) (***P=0.001, F-CAR-T vs. C-CAR-T, d17, unpaired student two-tailed t-test). B Tscm, Tcm, and Tem were characterized by surface staining of CD45RO and CD62L and analyzed with flow cytometry (***P<0.001 comparing F-CAR-T and C-CAR-T). C T-cell exhaustion was characterized by PD-1, LAG3, and TIM-3 staining; Statistical analyses of the percentage of PD1+ LAG3+ Tim3+ (***P<0.001, comparing F-CAR-T and C-CAR-T), unpaired student two-tailed t-test). D RTCA assay was used to examine the specific killing of HeLa-CD19 cells. Growth of target HeLa-CD19 or HeLa cells were monitored dynamically. E CD19+ target Nalm6-Luc cells or F Raji-Luc cells were co-cultured with either F-CAR-T or C-CAR-T for 6h. Target cell killing efficacy was calculated by luciferase activity. NS, P>0.05 F-CAR-T vs. C-CAR-T (unpaired student t-test, two-tailed). F-CAR-T FasT CAR-T, C-CAR-T conventional CAR-T, Tcm (CD45RO+CD62L+) T central memory cells, Tem (CD45RO+CD62L) T effector memory cells, Tscm (CD45ROCD62L+) T stem cell memory, PD1 programmed cell death protein 1, TIM-3 T cell immunoglobulin and mucin domain containing-3, LAG3 lymphocyte-activation gene 3, RTCA real-time cell analyzer, E:T effector cells: target cells, NT normal T-cell.

Phenotypes of unstimulated F-CAR-T from three healthy donors were analyzed by flow cytometry. The CD45ROCD62L+ population was 45.7%2.2% which was comparable to the un-transduced T-cells (data not shown). Upon stimulation with CD19+ tumor cells for 9 days, C-CAR-T central memory cells (Tcm, CD45RO+CD62L+ and effector memory cells (Tem, CD45RO+CD62L) were 56.62%11.97% and 40.48%9.70%, respectively, among the C-CAR-T cells (Fig. 1B and Figs. S2B and S2). In contrast, Tcm cells (87.92%4.36%) was predominant in F-CAR-T, with only a small fraction of Tem (7.84%3.79%). In addition, F-CAR-T cells demonstrated more abundant T stem cell memory (Tscm) (3.841.22% vs 2.342.48%, p<0.05) than C-CAR-T cells. We also examined the exhaustion status of the stimulated CAR-T cells. A higher percentage of PD-1+LAG3+Tim3+T-cells were detected in the C-CAR-T (11.19%2.54%) compared to F-CAR-T (3.59%2.51%, p<0.001) (Fig. 1C). Together these data indicated that the F-CAR-T exhibited a younger phenotype and was less exhausted compared to C-CAR-T.

We used a real-time cell analyzer (RTCA) assay to measure the cytotoxicity of F-CAR-T and C-CAR-T against CD19+ cells in vitro. F-CAR-T and C-CAR-T killing of Hela-CD19 target cells were comparable using this assay (Fig. 1D). Similar levels of IFN- and IL-2 production were also observed (Fig. S2D). In a luciferase-based cytotoxicity assay, CD19+ B leukemia cell lines, Raji and Nalm6, were both effectively killed to similar or better levels at different E:T ratios (Fig. 1E, F).

To compare the in vivo cytotoxicity of F-CAR-T and C-CAR-T, severe immunodeficient NOG mice were engrafted with Raji-luciferase cells. One week after the tumor grafts were established, F-CAR-T and C-CAR-T were intravenously injected at various doses. The engrafted tumors progressed aggressively in control groups with either vehicle alone or control T-cells (Fig. 2A). In contrast, F-CAR-T or C-CAR-T treatment greatly suppressed tumor growth in a dose-dependent manner (Fig. 2A). In the high dose group (2106/mice), both F-CAR-T and C-CAR-T eliminated the tumor rapidly. However, in the low dose group (5105/mice), F-CAR-T showed more effective tumor-killing compared to C-CAR-T. On day 20, mice in the low dose F-CAR-T group became tumor-free, while C-CAR-T treated mice exhibited tumor relapse (Fig. 2A). We examined the CAR-T cell expansion in vivo after infusion. As shown in Fig. 2B, both F-CAR-T and C-CAR-T began to expand in the peripheral blood 7 days after infusion. C-CAR-T cell numbers reached their peak on day 14 and receded on day 21. In contrast, the F-CAR-T cell number peaked on day 21 and declined to a baseline level on day 28. F-CAR-T not only persisted longer but also underwent 26 folds greater expansion than C-CAR-T (Fig. 2B).

A Raji-Luc cell engraftment NOG mice were given high dose (2106/mice, n=3) and low dose (5105/mice, n=3) F-CAR-T/C-CAR-T along with control groups. Tumor growth was monitored with IVIS scan once every 3 days; B CAR-T expansion in peripheral blood of mice was analyzed by flow cytometry (n=6). ***P<0.001 for F-CAR-T HD vs. C-CAR-T HD; F-CAR-T LD vs. C-CAR-T LD; F-CAR-T HD vs. F-CAR-T LD; C-CAR-T HD vs. C-CAR-T LD (two-way ANOVA statistical analysis); C Schematic of the Nalm6 (1106) xenograft model, CAR-T (2106) infused 1 day after cyclophosphamide (20mg/kg) treatment. Bone marrow infiltration of F-CAR-T was analyzed 10 days after CAR-T infusion (n=3); D CD45+CD2 F-CAR-T vs. C-CAR-T in peripheral blood of mice were analyzed by flow cytometry; *P<0.05 (unpaired student two-tailed t-test). IVIS in vivo imaging system, PB peripheral blood, i.v. intravenous, HD high dose, LD low dose, Cy cyclophosphamide; *p<0.05; #: number.

We examined the BM infiltration of F-CAR-T cells after infusion into Nalm6-bearing mice (Fig. 2C). A larger population of CAR-T cells was observed 10 days after infusion in BM in F-CAR-T infused group than that in the C-CAR-T group (p<0.05) (Fig. 2D), suggesting F-CAR-T cells possessed a better BM homing capability than C-CAR-T.

The chemokine receptor CXCR4 is known to be critical for BM homing of T-cells [25, 26]. Indeed, a higher percentage of CXCR4+ T cells were detected in F-CAR-T than in the C-CAR-T. Interestingly, this phenotype was more pronounced for CD4+ T cells than CD8+ T cells (Fig. S3A). In a two-chamber system, more F-CAR-T cells could be detected in the lower chamber than their C-CAR-T counterparts (Fig. S3B).

Between Jan. 2019 and Oct. 2019, 25 pediatric and adult patients with CD19+R/R B-ALL were enrolled onto our phase 1 trial, including two patients who had relapsed following a prior allo-HSCT. Patient characteristics are detailed in Table 1. The median age of patients was 20 (range: 344) years old. Twenty patients were >14 years old, and five were 14 years old. The median percentage of pre-treatment BM blasts was 9.05% (range: 0.1982.9%). As our pre-clinical studies demonstrated that F-CAR-T cells had a superior expansion capability as compared to C-CAR-T, we infused a relatively low doses of F-CAR-T cells, ranging from 104105 cells/kg: 3.0104 cells/kg (n=2), 6.5 (5.867.43)104 cells/kg (n=9), 1.01 (1.01.16)105 cells/kg (n=12), 1.52(1.471.56)105 cells/kg (n=2), (Fig. S4). The median time from apheresis to the infusion of CD19+F-CAR-T cells was 14 days (range: 1220). Although the manufacturing time of F-CAR-T was next day, the quality control time and detailed final product releases including sterility testing require a minimum of 710 days to complete. In addition, transportation of cell products requires approximately two days. Of the 25 patients who received CD19 F-CAR-T infusion, 22 (88%) received bridging chemotherapy between apheresis and lymphodepleting chemotherapy to control rapid disease progression (Table S3).

F-CAR-T cells were manufactured successfully for all patients. The mean transduction efficiency of F-CAR-T was 35.4% (range: 13.170.3%) (Fig. S5A). Both CD4+/CAR+ (mean, 49.6%; range: 13.673.2%) and CD8+/CAR+ (mean, 41.5%; range: 20.677.7%) subsets were present in the CD3+CAR+ T cell subsets of all products. The mean proportion of Tscm, Tem, and Tcm cells in the CD3+CAR+ T cell subsets of all products was 23.3% (range: 3.5545.3%), 33.2% (range: 17.267.9%), and 36.1% (range: 20.758.1%), respectively (Fig. S5B). F-CAR-T products exerted significant IFN- release and cytotoxic effects against the CD19+ cell line HELA-CD19 (Fig. S5, C, D).

All 25 infused patients experienced adverse events (AEs) of any grade, with 25 (100%) experiencing grade 3 or higher adverse events. No grade 5 events related to F-CAR-T treatment were observed (Table 2).

CRS occurred in 24 (96%) patients with 18 (72%) grade 12 CRS,6 (24%) of grade 3, and no grade 4 or higher CRS (Fig. S6). In the >14 years old group, 16/20 (80%) patients developed mild CRS, and only 2/20 (10%) developed grade 3 CRS. For 14 years old patients, 2/5 (40%) had mild CRS, yet 3/5 (60%) experienced grade 3 CRS (Table S4). ICANS was observed in 7 (28%) patients, with 2 (8%) grade 3 ICANS occurring in patients >14 years old and 5 (20%) grade 4 ICANS all occurring in patients 14 years old. No grade 5 ICANS was developed (Fig. S7 and Table S4). The most frequent presentation of CRS was fever, particularly a high fever of >39C. The first onset of CRS symptoms occurred between day 3 and 8 post-CAR-T infusion with a median onset at day 4 (range: 110 days). The most common symptoms of ICANS were seizure (5/7) and depressed consciousness (5/7). The median time to ICANS onset from CAR-T cell infusion was 7 days (range: 58), and the median time to resolution was 2 days (Fig. S7). All CRS and ICANS events were managed including early intervention when fever of 39C persisted for 24h. Sixteen (64%) patients received tocilizumab with a median total dose of 160mg (range: 160320mg). Twenty-one (84%) patients received corticosteroids including dexamethasone (median total dose, 43mg; range: 4127mg) and or methylprednisolone (median total dose, 190mg; range: 401070mg). The vast majority of these patients discontinued corticosteroids within 2 weeks. The change in IL-6, IFN-, IL-10, and GM-CSF levels after infusion are selectively shown in Fig. S8. The peak levels of these four cytokines were observed between day 710. Among all 21 cytokines examined, only post-infusion IL-6 levels were associated with moderate to severe CRS and/or ICANS (Figs. S9 and S10).

Superior in vivo proliferation and persistence of F-CAR-T compared to C-CAR-T cells were observed regardless of dose levels. The median peak level was reached on day 10 (range: 714 days) with 1.9105 transgene copies/g of genomic DNA (range: 0.225.2105 transgene copies/g of genomic DNA) by qPCR and 83 F-CAR-T cells per l blood (range: 42102 F-CAR-T cells per l blood) by FCM (Fig. 3A, B). No significant differences were observed among the different dose groups in the mean F-CAR-T copies peak (Fig. 3C). Importantly, there was no significant difference in the mean F-CAR-T copies peak between patients who received corticosteroids compared to those who did not (Fig. 3D).

A F-CAR-T cells in peripheral blood by qPCR. Purple, dose level 1; black, dose level 2; blue, dose level 3; red, dose level 4; B F-CAR-T cells in peripheral blood by flow cytometry. Purple, dose level 1; black, dose level 2; blue, dose level 3; red, dose level 4; C Comparison of the mean peak copy number of F-CAR-T cells in peripheral blood at each dose level. Statistical significance was determined by the MannWhitney test. D Comparison of the mean peak copy number of F-CAR-T cells in peripheral blood with or without steroids. Statistical significance was determined by the MannWhitney test.

Fourteen days after F-CAR-T cell infusion, all patients achieved morphologic CR including 2/25 with CR and 23/25 CR with incomplete hematologic recovery (CRi), which further improved to 11/25 CR and 14/25 CRi 28 days post F-CAR-T (Table 1 and Fig. 4). More importantly, 23/25 (92%) had the minimal residual disease (MRD)-negative remission on day 14 and day 28 after F-CAR-T treatment. Patients achieving remission through CAR-T were given the option to proceed to allo-HSCT. With a median time of 54 days (range: 4581 days) post F-CAR-T infusion, 20 of 23 patients with MRD-negative status decided to pursue consolidative allo-HSCT including one patient who received a 2nd transplant. As of 18 October 2021, with a median follow-up duration of 693 days (range: 84973 days) among the 20 patients who had received allo-HSCT, one patient relapsed on day 172 and died 3 months after relapse, and four patients died from transplant-related mortality (TRM) including infection (n=3) and chronic GVHD (n=1) on day 84, day 215, day 220, and day 312, respectively. The other 15 patients remained in MRD-negative CR with a median remission duration of 734 days (range: 208973) except for one who became MRD-positive on day 294 with CD19+ disease. Among the other three patients (F05, F06, F16), one remained in MRD-negative CR on day 304, one remained in MRD-negative CR until day 303, received allo-HSCT but died from an infection on day 505, and one was lost to follow-up after day 114. Two patients who had MRD-positive CR after infusion withdrew from the study on day 42 and day 44, respectively, to seek other studies.

Clinical outcomes and consolidative allo-HSCT for the 25 patients who were treated with F-CAR-T therapy are shown. On day 28, 23/25 patients achieved MRD-negative CR/CRi. With a median time of 54 days (range: 4581) post F-CAR-T infusion, 20 of 23 patients with MRD-negative status received consolidative allo-HSCT. Among the 20 patients, 1 patient (F23) relapsed on day 172 and died 3 months after relapse. Four patients (F04, F09, F11, F12) died from transplant-related mortality (TRM) including infection (n=3) and chronic GVHD (n=1) on day 84, day 215, day 220, and day 312, respectively. The remaining 15 patients were in MRD-negative CR except for one (F18) who became MRD-positive on day 294. Among the other 3 patients (F05, F06, F16), 1 remained MRD-negative CR on day 304, 1 remained in MRD-negative CR until day 303, received allo-HSCT, and subsequently died from an infection on day 505. One patient was lost to follow-up after day 114. MRD minimal residual disease, CR complete remission, Allo-HSCT allogeneic hematopoietic stem cell transplantation.

F-CAR-T/T ratio in cerebrospinal fluid (CSF) was evaluated by FCM in 13/25 patients with available samples (Table S5). Between days 10 and 32, 9 patients were found to have considerable F-CAR-T penetration in their CSF, ranging from 40.65 to 79.2%, including 4 who developed severe ICANS. Among the other 4 patients, F-CAR-T cell abundance in the CSF ranged from 1.29% to 3.57%, and none experienced severe ICANS. Patients with higher levels of CAR-T in PB on day 10 consistently had higher levels of CAR-T in CSF with the exception of patient F15. Notably, CAR-T cells were still detectable in the CSF on day 101 with a 2.36% CAR-T/T ratio in patient F06, who also had undetectable circulating CAR-T cells at the same time.

In addition, concentrations of seven cytokines (IL-1b, IL-6, IL-10, IFN-, TNF-, MCP-1, and GM-CSF) in CSF samples from the above 10 of 13 patients were measured. Specifically, IL-1b was not detected in any of the 10 patients, and only one patient had detectable GM-CSF. For the other five cytokines, patients with severe ICANS had higher IL-6 levels in contrast to patients without severe ICANS, and the difference between the median level of IL-6 among these two groups of patients was statistically significant (Fig. S11). We did not observe significant differences among the other 4 cytokines between the two groups of patients. No clear relation between the CSF cytokine levels and the F-CAR-T/T % was observed.

View post:
Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study | Blood Cancer Journal...

Proteases implicated in ulcerative colitis – ASBMB Today

Ulcerative colitis, or UC, is a form of inflammatory bowel disease characterized by chronic and relapsing large intestine inflammation. Genetics account for only a minority of UC cases; hence, to develop treatments, researchers need to understand better the environmental contributions to this condition.

Gut microbes are in perpetual contact with the gastrointestinal tract, so they comprise important but poorly defined environmental variables contributing to UC development. Many studies have reported changes in gut microbiome composition in patients with UC compared to healthy individuals. While that suggests a potential role for gut microbes in UC pathogenesis, researchers have yet to pinpoint the causative microbes and associated bacterial proteins.

Dennis Wolans lab at Scripps Research is interested in identifying small-molecule activators and inhibiting bacterial enzymes involved in proliferation of human disease. Wolan said he was curious about what bacterial enzymes of the microbiome contribute to UC development.

Many publications have focused on the role of the microbiome in both health and disease states, he said. Most of these were focused on the taxonomical and phylogenic differences in the microbiome. But what about the associated bacterial proteins? What proteins are these gut bacteria making in disease conditions, and how are these interacting with the human body?

One protein of interest was serine proteases, a type of proteolytic enzyme that cleaves peptides at the serine amino acid. Researchers long have recognized that they coordinate many physiological processes and play key roles in regulating the inflammatory response. Previous studies have suggested increased proteolytic activity in microbial samples harvested from people with inflammatory disorders such as UC and Crohns disease.

Peter ThuyBuon, a graduate student and later a postdoc in the Wolan lab, led a project to study differential protein expression in healthy and UC fecal samples. He and the team described the project in a recent paper in the journal Molecular & Cellular Proteomics. In addition to standard mass spectrometry, ThuyBuon used a small molecular approach called affinity-based proteomic profiling to target and enrich for different types of proteases in the fecal samples.

We showed that there were 176 discrete host and microbial protein groups differentially enriched between healthy and UC patients, Wolan said. Furthermore, further enrichment of these proteins showed significantly higher levels of serine proteases in UC patients.

This finding has inspired exciting future research questions. For example, are elevated serine proteases the driver of UC or merely the effect of UC disease progression?

There is a lot of exciting work to be done using these findings, Wolan said. Future molecular studies should focus on how serine proteases might be contributing to UC and whether their levels can be manipulated to modify disease progression.

Functional proteomics has shown the potential role of serine proteases in UC. Future steps will include drug discovery and design of small-molecule regulators of bacterial enzymes.

Wolan said, Ultimately, the moderation of microbiome distribution in UC via external small-molecule intervention can serve as a foundation for UC prevention and treatment.

Read more here:
Proteases implicated in ulcerative colitis - ASBMB Today

Cutting Edge: Poop therapy can save your gut, and your life – The Indian Express

The very thought of getting someone elses poop transfused in your body may make you cringe but stool transplant has not only helped patients with gastrointestinal tract issues, it has also saved those who have had bone marrow transplants.

At Deenanath Mangeshkar Hospitals Centre of Excellence in Infectious Diseases and Department of Haematology, Pune, seven of the 11 patients of bone marrow transplants developed Clostridium difficile infection. They were treated with faecal microbial transplant (FMT), also referred to as stool transplant, over the past year.

Research worldwide has shown that a faecal transplant can restore healthy bacteria in the lower intestine which can help control Clostridium difficile or C. diff. According to the Johns Hopkins University School of Medicine, FMT can be more effective than antibiotics for keeping C. diff in check in some cases.

Since C. diff infection can recur and cause colitis (inflammation in the colon), FMT restores good and healthy bacteria, said Dr Parikshit Prayag, infectious disease consultant and in-charge of the Centre of Excellence in Infectious Diseases at Deenanath Mangeshkar hospital.

Dr Sameer Melinkeri, head of the department of haemotology at the hospital, said C. diff infection-related diarrhoea can occur in a normal setting in which antibiotics can be used for treatment. However, antibiotic treatment for recurrent infections can involve one or more courses of medication and their effectiveness comes down with each subsequent bout. FMT can arrest such infections post bone marrow transplant as it can be life-threatening, he added.

FMT is also done for certain disease conditions like Graft vs host disease (GvHD). Most people who undergo a bone marrow transplant suffer from blood cancer. Graft vs host disease can occur at any time after an allogeneic transplant where the donated bone marrow or peripheral stem cells can attack the recipients body. It can develop in the GI tract, skin or liver, Dr Prayag said.

Latest research published in the Journal of International Medical Research and others has shown how FMT is a promising treatment for patients with steroid-resistant GvHD. We have seen clinically relevant results in six of our patients, Dr Prayag said.

So, who can be donors? They are selected based on certain parameters. They should not be immune-compromised or have taken antibiotics over the past six months, says Dr Sampada Patwardhan, head of the department of microbiology at the hospital. Donor screening has to be done carefully. We need to rule out infections, she said.

Procedures on the transplant delivery methods may vary like colonoscopy and use of nasojejunal tube. The recovery may take a week or more and in most cases there are at least two weekly installations of the stool (in liquid form).

Very few centres conduct FMT and among them, the centre at Deenanath Hospital actively treats cases involving bone marrow transplants. At a recent virtual meeting of the International Society of Blood Transfusion, Dr Prayag made a strong case for encouraging stool transplants. The condition of C. diff is also underdiagnosed in the country as there isnt adequate infrastructure to correctly detect the problem, he pointed out.

In fact, FMT is being touted as a treatment option for many gut health issues. In an opinion article published on June 30 in the journal Trends in Molecular Medicine, a team from Harvard Medical School and Brigham and Womens Hospital (BWH) proposes that individuals bank samples of their own gut microbiota when they are young and healthy for potential use later in life in an autologous FMT.

A report in Science Daily quotes corresponding author Yang-Yu Liu, an associate professor of medicine at Harvard and an associate scientist in the Channing Division of Network Medicine at BWH, as saying, The idea of rewilding the human microbiome has taken off in recent years and has been hotly debated from medical, ethical and evolutionary perspectives. It is still unknown if people in industrialized societies can gain some health benefit by restoring their microbiome to an ancestral state. In this paper, we proposed a way to rejuvenate the human gut microbiome.

The report also listed OpenBiome, a non-profit stool bank based in Somerville, Massachusetts, as the first stool bank to offer an option for individuals to bank their own stool for future treatment of C. diff infection. Yang and his colleagues are now looking at if this treatment can be used for other diseases.

Conceptually, the idea of stool banking for autologous FMT is similar to when parents bank their babys cord blood for possible future use. However, there is greater potential for stool banking, and we anticipate that the chance of using stool samples is much higher than for cord blood. But there are many practical issues to implementing this idea, Yang is quoted as saying, hinting at optimal storage and cryopreservation issues.

Read the rest here:
Cutting Edge: Poop therapy can save your gut, and your life - The Indian Express

The Origins of Our Blood May Not Be What We Thought – SciTechDaily

Clusters of the earliest hematopoietic cells being born in the walls of the umbilical artery of a mouse embryo. The cells colored in red represent embryonic multipotent progenitor cells (eMPPs). Credit: Sachin H. Patel/Boston Childrens Hospital

Barcoding studies discovered two independent sources for blood cells in mice. If confirmed in humans, our understanding of blood cancers, bone marrow transplants, and the aging immune system will change.

The origins of our blood may not be quite what we thought. Using cellular barcoding in mice, groundbreaking research finds that blood cells originate not from one type of mother cell, but two, with potential implications for blood cancers, bone marrow transplant, and immunology. Fernando Camargo, PhD, of the Stem Cell Program at Boston Childrens Hospital led the study, published in the journal Nature on June 15, 2022.

Historically, people have believed that most of our blood comes from a very small number of cells that eventually become blood stem cells, also known as hematopoietic stem cells, says Camargo, who is also a member of the Harvard Stem Cell Institute and a professor at Harvard University. We were surprised to find another group of progenitor cells that do not come from stem cells. They make most of the blood in fetal life until young adulthood, and then gradually start decreasing.

The researchers are now following up to see if the findings also apply to humans. If so, these cells, known as embryonic multipotent progenitor cells (eMPPs), could potentially inform new treatments for boosting aging peoples immune systems. They could also shed new light on blood cancers, especially those in children, and help make bone marrow transplants more effective.

Camargos team applied a barcoding technique they developed several years ago. Using either an enzyme known as transposase or CRISPR gene editing, they inserted unique genetic sequences into embryonic mouse cells in such a way that all the cells descended from them also carried those sequences. This enabled the team to track the emergence of all the different types of blood cells and where they came from, all the way to adulthood.

Previously, people didnt have these tools, says Camargo. Also, the idea that stem cells give rise to all the blood cells was so embedded in the field that no one attempted to question it. By tracking what happened in mice over time, we were able to see new biology.

Through barcoding, the researchers found that eMPPs, as compared with blood stem cells, are a more abundant source of most lymphoid cells important to the immune responses, such as B cells and T cells. Camargo believes the decrease in eMPPs that they observed with age may explain why peoples immunity weakens as they get older.

Were now trying to understand why these cells peter out in middle age, which could potentially allow us to manipulate them with the goal of rejuvenating the immune system, says Camargo.

In theory, there could be two approaches: extending the life of eMPP cells, perhaps through growth factors or immune signaling molecules, or treating blood stem cells with gene therapy or other approaches to make them more like eMPPs.

Camargo is also excited about the potential implications for better understanding and treating blood cancers. For example, myeloid leukemias, striking mostly older people, affect myeloid blood cells such as granulocytes and monocytes. Camargo thinks these leukemias may originate from blood stem cells, and that leukemias in children, which are mostly lymphoid leukemias, may originate from eMPPs.

We are following up to try to understand the consequences of mutations that lead to leukemia by looking at their effects in both blood stem cells and eMPPs in mice, he says. We want to see if the leukemias that arise from these different cells of origin are different lymphoid-like or myeloid-like.

Finally, the recognition that there are two types of mother cells in the blood could revolutionize bone marrow transplant.

When we tried to do bone marrow transplants in mice, we found that the eMPPs didnt engraft well; they only lasted a few weeks, says Camargo. If we could add a few genes to get eMPPs to engraft long term, they could potentially be a better source for a bone marrow transplant. They are more common in younger marrow donors than blood stem cells, and they are primed to produce lymphoid cells, which could lead to better reconstitution of the immune system and fewer infection complications after the graft.

Reference: Lifelong multilineage contribution by embryonic-born blood progenitors by Sachin H. Patel, Constantina Christodoulou, Caleb Weinreb, Qi Yu, Edroaldo Lummertz da Rocha, Brian J. Pepe-Mooney, Sarah Bowling, Li Li, Fernando G. Osorio, George Q. Daley and Fernando D. Camargo, 15 June 2022, Nature.DOI: 10.1038/s41586-022-04804-z

Sachin H. Patel, MD, PhD, of the Stem Cell Program (now at University of California San Francisco) and Constantina Christodoulou, PhD (now at Bristol Myers Squibb) were co-first authors on the paper. The study was funded by the National Institutes of Health (HL128850-01A1, P01HL13147), the Evans MDS Foundation, the Alex Lemonade Foundation, the Leukemia and Lymphoma Society, and the Howard Hughes Medical Institute. The authors declare no competing interests.

Here is the original post:
The Origins of Our Blood May Not Be What We Thought - SciTechDaily

Bone Marrow Aspirate Concentrates Market: Increasing Use in Orthopedic Surgery Applications to Drive Sales in the Global Market – BioSpace

Wilmington, Delaware, United States: The global bone marrow aspirate concentrates market was valued around US$ 130.0 Mn in 2016 is anticipated to register a stable CAGR of over 5.0% during forecast period of 2017 to 2025, according to a new report published by Transparency Market Research (TMR) titled Bone Marrow Aspirate Concentrates Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 20172025. Growth of the global bone marrow aspirate concentrates market is driven by increased prevalence of and incidences of orthopedic diseases, and sports injuries, along with high growth of the cosmetic surgery industry and increasing applications of the BMAC products in the cosmetic and orthopedic surgeries. The bone marrow aspirate concentrates market in Asia Pacific is expanding with a high potential to grow registering a CAGR above 6.0% on the backdrop of unmet clinical needs, rising geriatric population, large patient pool, favorable government regulations, development in health care sector, and increased focus on research and developmental activities.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=40451

Increase in incidences of Osteoarthritis on the backdrop of rising geriatric population to drive market growth

According to a collaborative survey conducted by the United Nations and the World Health Organization, 1.2 billion people in China are suffering from OA, of which more than 55% are aged 60 years or above. On the backdrop of such a huge patient base, there has been several developments in the field orthopedic surgery. Bone marrow-derived stem cell treatment is considered a promising and advanced therapy. It reduces the injury healing time in orthopedic diseases to five to six weeks from four to six months in case of surgery. Reduction in the healing time is a factor likely to propel the Bone Marrow Aspirate Concentrates market during the forecast period. However, pain associated with the treatment, lack of product approval, and preference for alternative treatments are negatively affecting the market growth. Moreover, high investments in R&D and clinical trials, slow approval processes entailing sunken costs, and marginal returns on investment (RoI) for stakeholders are primary concerns faced by manufacturer further hampering growth of the market.

Request Sample of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=40451

Rise in the Number of BMAC Assisted Procedures to Boost Growth of Bone Marrow Aspirate Concentrates Accessories Segment

The product type segment is fragmented into bone marrow aspirate concentrates systems and bone marrow aspirate concentrates accessories. The bone marrow aspirate concentrates accessories segment is anticipated to carry major share of the market on the backdrop of rise in number of BMAC assisted procedures. Cell therapies have been used extensively over the past decade for a variety of medical applications to restore cellular function and enhance quality of life. Owing to the differentiation property, stem cells are being used for repair and regeneration of bone. Moreover, increase in awareness about hygiene and risk of cross-contamination in developing countries such as Brazil, China and India are expected to increase the use of single-use Jamshidi needles for bone marrow stem cell procedures. This is likely to fuel the growth of the accessories segment in the near future.

Request for Analysis of COVID-19 Impact on Bone Marrow Aspirate Concentrates Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=40451

Orthopedic Surgery Application to Dominate the Global Bone Marrow Aspirate Concentrates Market

The application segment of global bone marrow aspirate concentrates market is divided into orthopedic surgery, wound healing, chronic pain, peripheral vascular disease, dermatology, and others applications. Of which, orthopedic surgery segment is anticipated to dominate the market owing to rising geriatric population, and surge in incidences of osteoarthritis around the globe. The dermatology segment is anticipated to expand at the highest CAGR of over 6.0% during forecast period of 2017 to 2025 owing to current boom in the industry, increase in disposable income, and technological advancements in the market. The utilization of the regenerative ability of fibroblasts and keratinocytes from human skin has formed new ways to develop cell-based therapies for patients. Moreover, capacity of bone marrow derived extra-cutaneous cells is being researched for its plasticity in regenerating skin; it is likely to lead to the future growth of cell therapies in dermatology.

Rise in Healthcare Expenditure to Fuel Growth of Hospitals & Clinics End-user Segment

In terms of end-users, market is divided into hospitals & clinics, pharmaceutical & biotechnology companies, Contract Research Organizations (CROs) & Contract Manufacturing Organizations (CMOs), and academic & research institutes. The hospitals & clinics segment dominated the bone marrow aspirate concentrates market in 2016. The trend is expected to continue during the forecast period. The hospitals & clinics segment is likely to be followed by the biotechnology & biopharmaceutical companies segment in terms of market share during the forecast period. The segment is anticipated to hold more than 8.0% of market share in 2016. Growth of the segment is attributed to increasing number of biotechnology companies and rising partnerships among the market players to expand global presence.

Make an Enquiry Before Buying - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=40451

Large Patient Pool in Developing Countries Like China, India, Brazil, and Taiwan to Create More Opportunities in the Market

Geographically, global bone marrow aspirate concentrates market is divided into major five geographical regions, including North America, Europe, Asia-Pacific, Latin America and Middle East and Africa. North America is anticipated to hold major share of the market owing to technological advancements and regulatory approval for new devices, awareness about stem cell therapy, and rise in number of cosmetic surgical procedures. While, Asia Pacific orthopedic market is at a pivotal point today, which was valued around US$ 19 Million in 2016 and anticipated to derive massive and augmented growth. The orthopedic market in Asia, including bone graft, spine, and bone substitute, is anticipated to grow more than twice as fast as the overall orthopedic market which will further boost growth of BMAC market in the region.

Semi-consolidated Market with 3-4 key Players Operating in the BMAC Systems Market Segment

Key players covered in this report are Terumo Corporation (Terumo BCT), Ranfac Corp., Arthrex, Inc., Globus Medical, Inc., Cesca Therapeutics Inc., MK Alliance Inc. (TotipotentSC), and Zimmer Biomet Holdings, Inc. Companies operating in the global market for bone marrow aspirate concentrates are focusing on in-licensing and collaboration agreements to put new products in the developing markets like Asia Pacific, and Latin America. For instance, in August 2017, Cesca Therapeutics Inc. announced a distribution agreement with Boyalife WSN Ltd., a China based company. Through this agreement, Boyalife WSN Ltd. will distribute Cescas innovative biobanking and point-of-care solutions in China, India, Singapore, and the Philippines. As India and China represent two of the fastest growing economies in the world, successful penetration of these regions can generate more market opportunity to the companies.

More Trending Reports by Transparency Market Research

Brucellosis Vaccine Market: https://www.transparencymarketresearch.com/brucellosis-vaccines-market.html

Solitary Fibrous Tumor Treatment Market: https://www.transparencymarketresearch.com/solitary-fibrous-tumor-treatment-market.html

Post operative Pain Therapeutics Market: https://www.transparencymarketresearch.com/postoperative-pain-therapeutics-market.html

ACL Reconstruction Procedures Market: https://www.transparencymarketresearch.com/acl-reconstruction-procedures-market.html

CAR T cell Therapy Market: https://www.transparencymarketresearch.com/car-t-cell-therapy-market.html

Retinal Vein Occlusion Market: https://www.transparencymarketresearch.com/retinal-vein-occlusion-market.html

Adrenocorticotropic Hormone [ACTH] Market: https://www.transparencymarketresearch.com/adrenocorticotropic-hormone-market.html

Veterinary Supplements Market: https://www.transparencymarketresearch.com/veterinary-supplements-market.html

About Us

Transparency Market Research is a global market research firm offering the latest market research reports and business consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact Us

Rohit Bhisey

Transparency Market Research Inc.

CORPORATE HEADQUARTER DOWNTOWN,

1000 N. West Street,

Suite 1200, Wilmington, Delaware 19801 USA

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

Continue reading here:
Bone Marrow Aspirate Concentrates Market: Increasing Use in Orthopedic Surgery Applications to Drive Sales in the Global Market - BioSpace

What you need to know about Non-Hodgin’s Lymphoma – NewsPatrolling

Non-Hodgkins Lymphoma, also known as NHL, is a cancer that starts in the white blood cells in the lymphatic system. White blood cells are responsible for shielding the body from germs and is critical to the immune system. When cancer cells start multiplying in these lymphocytes, the tumours can spread throughout the body, eventually attacking every organ.

NHL is a broader term used to define the various lymphomas affecting the lymphatic system, including the lymph nodes and lymph tissue. Lymphoma can begin anywhere in the body, wherever the lymphatic tissue is found and is mainly seen in adults. Lymph nodes, spleen, adenoids, tonsils, bone marrow, thymus, and digestive tract are where the Lymphoma can start before affecting the entire system.

Classification of Lymphomas

There are several types of Non-Hodgkins Lymphoma, and while classifying a Lymphoma, the doctors consider a few points. Lymphomas can be categorized based on:

The type of lymphocyte the Lymphoma emerged from.

Structure of Lymphoma under the microscope.

The features of chromosomes in the lymphoma cell, and

Presence of specific proteins on the surface of the cancer cells.

Types of Lymphomas

The types of lymphomas are distinguished based on the type of the lymphocytes affected. There are two basic types of lymphocytes The T-cells and the B-cells. T cells protect us from infection and the B cells create antibodies to neutralize the infection- causing germs.

The types of lymphoma include:

The Chronic Lymphocytic Leukemia or CLL is cancer of the blood and bone marrow, and it generally progresses slower when compared to other types of leukemia. In this type of cancer, the white blood cells get affected and are often seen in older adults. Chronic lymphocytic leukemia doesnt present with any symptoms at the initial stages, but swollen lymph nodes, coupled with fatigue, fever, and unintended weight loss are some common signs.

Closely related to the CLL is Small Lymphocytic Lymphoma, or SLL, found in the lymph nodes and the spleen.

A rare type of cancer, Cutaneous B-cell Lymphoma, begins in white blood cells, specifically in one kind of germ-fighting lymphocyte called B cells or B lymphocytes. This cancer presents itself as a thick bump, the same as ones skin color or pink or purple, and is located under the skin.

Also known as CTCL, the Cutaneous T cell Lymphoma begins in the white blood cells but in T lymphocytes, attacking the skin. CTCL often presents with rash, redness on the skin, scaly patches, and small tumours under the skin.

Follicular Lymphoma is a sluggish or a slow-growing type of cancer and is often found in people aged above 60. These cancers occur either in lymph nodes or in the bone marrow. If not treated on time, follicular lymphomas can grow fast, diffusing large B-cells.

Causes of Non-Hodgkins Lymphoma

It is tough to pinpoint a single causative factor for Non-Hodgkins Lymphoma. This cancer begins either in B cells or T cells in the lymphatic system.

Most Common Risk Factors

Patients on immunosuppressive medications administered after an organ transplant are at high risk of developing Non-Hodgkins Lymphoma.

Patients with a history of certain viruses and bacterial infections, including HIV, Epstein-Barr, and Helicobacter pylori, are prone to this type of cancer.

Overexposure to certain chemical compounds in pesticides used for killing insects may up the risk of Lymphoma.

Though Non-Hodgkins Lymphoma can happen at any age, it is often diagnosed in people above 60 years of age.

Diagnosis

Non-Hodgkins Lymphoma is diagnosed through blood tests and imaging tests like CT, MRI and PET-CT. Minimally invasive diagnostic procedures like lymph node tests, bone marrow tests, and lumbar puncture are also done for collecting samples and reviewing them in labs for accurate diagnosis.

Treating Non-Hodgkins Lymphoma

Chemotherapy:

Chemotherapy is the first line of treatment for this type of cancer. It is often administered as a part of a bone marrow transplant where high dosage of chemotherapy kills cancer cells and act as a precursor to the transplant.

Radiation Therapy

Radiation therapy which involves high-powered energy beams being used to target cancer cells is recommended in the case of indolent NHL. It is used subsequently in chemotherapy, often aimed at the affected lymph nodes to curtail its progression.

Targeted Drug Therapy

Targeted drug therapy uses certain medications that block abnormalities in the cancer cells and make them die and is often combined with chemotherapy.

Bone Marrow Transplant

Also known as stem cell transplant, a bone marrow transplant is done by infusing healthy bone marrow stem cells from a donor into the patients body. These bone marrow cells aid in rebuilding bone marrow and are prescribed if other treatments fail to give the desired outcome.

Immunotherapy

Immunotherapy is recommended in the specific type of NHL where proteins produced by the cancer cells hide from the immune system. Immunotherapy disrupts the job of these proteins and makes the immune system fight the malignant cells. The treatment methods in combating Non-Hodgkins Lymphoma have come a long way in the recent decade.

It is advisable to consult a healthcare expert immediately in case of any of the symptoms.

BY: Dr. Prasad Gunari, Senior Consultant Medical Oncology, HCG NMR Cancer Centre, Hubli.

Read the rest here:
What you need to know about Non-Hodgin's Lymphoma - NewsPatrolling

Experts offer hope to vitiligo patients – The New Indian Express

Express News Service

BENGALURU: Vitiligo, a skin de-pigmentation disorder which affects 0.1 to 8% of population, is a cause of worry especially for women as it mainly affects face, neck and hands. It relapses in 40% of patients, within a year after stopping treatment. But Mesenchymal stem cell-based therapy can be a hope, experts say.

On World Vitiligo Day on Saturday, dermatologist, Aster R V Hospital, Dr Sunil Prabhu said the disorder is affecting at least 2.16% of children/adolescents. Vitiligo is a long-term condition, where pale white patches develop on the skin due to lack of melanin pigment. According to Dr Praveen Bharadwaj, dermatology consultant, Manipal Hospital, Whitefield, vitiligo is a condition in which the patients immune system weakens which affects the normal functioning of melanin producing cells.

Dr Bharadwaj explained, Mesenchymal stem cells, which are multi-potent adult stem cells, are found in bone marrow, fat tissues, umbilical cord and human foreskin. They are promising agents for therapy for the re-pigmentation of skin in vitiligo. This therapy reduces the main trigger of vitiligo that is immune-mediated melanocyte degeneration (stopping the immune destruction of melanocytes which produces melanin), promotes melanocytes and prevents relapse of the condition, he said.

Link:
Experts offer hope to vitiligo patients - The New Indian Express

Expert Cancer Homoeo Clinic Helping Patients with Aplastic Anaemia through Homoeopathic Treatment – Digital Journal

Expert Cancer Homoeo Clinic is delivering impactful homoeopathic treatment in the country for various diseases and disorders that include aplastic anaemia caused by a bone marrow injury.

Expert Cancer Homoeo Clinic was established in 1979 by Dr. Devendra Singh to cure chronic and dreaded diseases like neck cancer, gastrointestinal cancer, blood cancer and prostate cancer by homoeopathy. This chain of homoeopathic clinics has now expanded to possess many experienced physicians who are consistently ranked as the top cancer doctors in the world and who are trained in prestigious medical schools and research centres. Expert Cancer Homoeo Clinic offers advanced oncology care in a humane environment to its patients.

During a press interview organized recently, the spokesperson of Expert Cancer Homoeo Clinic shared, Our homoeopathic treatment is now also available for the rare disease of aplastic anaemia, in which the bone marrow and its hematopoietic stem cells get damaged. This causes a deficiency of all three blood cell types red blood cells, white blood cells, and platelets. Aplastic means the inability of stem cells to generate mature blood cells. Our homoeopathic medicines have proven to be quite effective on this type of disease.

Expert Cancer Homoeo Clinic has the top homoeopathic doctor in Indiato deliver the right treatment according to the factors that may have caused aplastic anaemia. Generally, the factors that can temporarily or permanently injure the bone marrow and affect the blood cell production include radiation and chemotherapy treatments, exposure to toxic chemicals, use of certain drugs, autoimmune disorders, a viral infection, and pregnancy with an autoimmune problem. There are also unknown factors leading to idiopathic aplastic anaemia disease.

The spokesperson additionally stated, Aplastic anaemia can progress slowly over weeks or months, or it may come on suddenly. The illness may be brief, or it may become chronic. Aplastic anaemia can be very severe and even fatal. Thus, it is always advisable to meet a doctor for timely treatment, if the patient notices the symptoms. Some of its symptoms are shortness of breath with exertion, fatigue, rapid or irregular heart rate, pale skin, unexplained or easy bruising, frequent or prolonged infections, nosebleed, dizziness, and skin rashes.

Expert Cancer Homoeo Clinic suggests the aplastic anaemia treatment in homoeopathythat can stimulate the healthy portion of bone marrow to improve cell production. This may help to reduce the number of blood transfusions. Homoeopathy medicines improve the patients general vitality and well-being and help them to fight infections. These medicines control the bleeding disorder associated with aplastic anaemia. The clinic gives the medicinal treatment that is beneficial in countering the side effects associated with conventional therapy. The chances of relapse also significantly diminish with the homoeopathic treatment of aplastic anaemia.

About Expert Cancer Homoeo Clinic:

Expert Cancer Homoeo Clinic is a chain of homoeopathy clinics in India. The clinic offers treatment for several dreaded diseases, ranging from all types of cancer to kidney diseases. Whether the patients require effective migraine treatment in Delhi or need to schedule an appointment with the best cancer doctor in Mumbai, they can do it all with the Expert Cancer Homoeo Clinic. The clinic follows a holistic treatment approach, ensuring complete healing.

Contact Information:

Expert Cancer Homoeo Clinic

Address Lucknow Centre: Opposite Picadilly Hotel, Kanpur-Lucknow Road, Bara Birwa, Jafar Khera, Alambagh, Lucknow, Uttar Pradesh, India

Phone (Mb): +91-9616385385 (Lucknow)

Address Delhi Centre: 101, Ashish Complex, Opposite Cafe Coffee Day, Near Alchon Public School, Mayur Vihar Phase 1, New Delhi, India

Phone: +91-9560062231 (Delhi)

Address Mumbai Centre: 504 Sunshine, Opp. Shastri Nagar, Lokhandwala, Andheri West, Mumbai, India

Phone: +91-8176813454 (Mumbai)

Email: [emailprotected] (Delhi) / [emailprotected] (Mumbai) / [emailprotected](Lucknow)

Website: http://cancerhomoeoclinic.co.in/

Media ContactCompany Name: Expert Cancer Homoeo ClinicContact Person: Dr. Devendra Singh Email: Send EmailPhone: +91-8176813454Address:504 Sunshine, Opp Shastri Nagar, Lokhandwala, Andheri West City: MumbaiState: MaharashtraCountry: IndiaWebsite: cancerhomoeoclinic.co.in

View original post here:
Expert Cancer Homoeo Clinic Helping Patients with Aplastic Anaemia through Homoeopathic Treatment - Digital Journal

Jasper Therapeutics to Participate in the William Blair 42nd Annual Growth Stock Conference – GuruFocus.com

REDWOOD CITY, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. ( JSPR), a biotechnology company focused on enabling cures with stem cell therapies, today announced that the Company is participating in the William Blair 42nd Annual Growth Stock Conference, to be held in Chicago from June 6-9, 2022.

Ronald Martell, Jaspers Chief Executive Officer, is scheduled to present on Thursday, June 9th at 8:00AM CT, with a breakout session to follow at 8:40AM CT. A live webcast of the presentation will be available at https://wsw.com/webcast/blair66/jasp/1933236 and at the Companys Investor Events webpage.

About Jasper TherapeuticsJasper Therapeutics, Inc. is a biotechnology company focused on the development of novel curative therapies based on the biology of the hematopoietic stem cell. The company is advancing two potentially groundbreaking programs. JSP191, an anti-CD117 monoclonal antibody, is in clinical development as a conditioning agent that clears hematopoietic stem cells from bone marrow in patients undergoing hematopoietic cell transplantation. It is designed to enable safer and more effective, and potentially curative, allogeneic hematopoietic cell transplants and gene therapies. A clinical study of JSP191 as a novel, disease-modifying, therapeutic for patients with lower risk MDS is also planned to begin in 2022. In parallel, Jasper Therapeutics, Inc. is advancing its preclinical mRNA hematopoietic stem cell grafts platform, which is designed to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. Both innovative programs have the potential to transform the field and expand hematopoietic stem cell therapy cures to a greater number of patients with life-threatening cancers, genetic diseases and autoimmune diseases than is possible today. For more information, please visit us at jaspertherapeutics.com.

Forward-Looking StatementsCertain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as believe, may, will, estimate, continue, anticipate, intend, expect, should, would, plan, predict, potential, seem, seek, future, outlook and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the potential of the Companys JSP191 and mRNA engineered stem cell graft programs. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Jasper and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Jasper. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political and business conditions; the risk that the potential product candidates that Jasper develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Jaspers product candidates; the risk that prior study results may not be replicated; the risk that clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; the risk that Jasper will be unable to successfully market or gain market acceptance of its product candidates; the risk that Jaspers product candidates may not be beneficial to patients or successfully commercialized; patients willingness to try new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on Jaspers business; the risk that third parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical services will fail to perform satisfactorily; the risk that Jaspers business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics, including the ongoing COVID-19 pandemic; the risk that Jasper will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or will infringe the intellectual property protection of others; and other risks and uncertainties indicated from time to time in Jaspers filings with the SEC. If any of these risks materialize or Jaspers assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While Jasper may elect to update these forward-looking statements at some point in the future, Jasper specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Jaspers assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Contacts:

John Mullaly (investors)LifeSci Advisors617-429-3548[emailprotected]

Jeet Mahal (investors)Jasper Therapeutics650-549-1403[emailprotected]

Visit link:
Jasper Therapeutics to Participate in the William Blair 42nd Annual Growth Stock Conference - GuruFocus.com

What New Advances are there in 3D Bioprinting Tissues? – AZoM

A paper recently published in the journal Biomaterials reviewed the new advances in three-dimensional bioprinting (3DBP) for regenerative therapy in different organ systems.

Study:Advances in 3D bioprinting of tissues/organs for regenerative medicine and in-vitro models. Image Credit:luchschenF/Shutterstock.com

Organ/tissue shortage has emerged as a significant challenge in the medical field due to patient immune rejections and donor scarcity. Moreover, mimicking or predicting the human disease condition in the animal models is difficult during preclinical trials owing to the differences in the disease phenotype between animals and humans.

3DBP has gained significant attention as a highly-efficient multidisciplinary technology to fabricate 3D biological tissue with complex composition and architecture. This technology allows precise assembly and deposition of biomaterials with donor/patients cells, leading to the successful fabrication of organ/tissue-like structures, preclinical implants, and in vitro models.

In this study, researchers reviewed the 3DBP strategies currently used for regenerative therapy in eight organ systems, including urinary, respiratory, gastrointestinal, exocrine and endocrine, integumentary, skeletal, cardiovascular, and nervous systems. Researchers also focused on the application of 3DBP to fabricate in vitro models. The concept of in situ 3DBP was discussed.

In this extensively used low-cost bioprinting method, rotating screw gear or pressurized air is used without or with temperature to extrude a continuous stream of thermoplastic or semisolid material. Different materials can be printed at a high fabrication speed using this technology. However, low cell viability and the need for post-processing are the major drawbacks of extrusion bioprinting.

In this method, liquid drops are ejected on a substrate by acoustic or thermal forces. High fabrication speed, small droplet volume, and interconnected micro-porosity gradient in the fabricated 3D structures are the main advantages of this technique. However, limited printed materials and clogging are the biggest drawbacks of inkjet bioprinting.

A laser is used to induce the forward transfer of biomaterials on a solid surface in the laser-assisted bioprinting method. High cell viability and nozzle-free noncontact process are the biggest advantages of laser-assisted bioprinting, while metallic particle contamination and the time-consuming nature of the printing process are the major disadvantages.

Several studies were performed involving the development of neuronal tissues using the 3DBP method. The pressure extrusion/syringe extrusion (PE/SE) bioprinting technique was used for central nervous tissue (CNS) tissue replacement. The layered porous structure was fabricated using glial cells derived using human induced pluripotent stem cell (iPSC) and a novel bioink based on agarose, alginate, and carboxymethyl chitosan (CMC) formed synaptic networks and displayed a bicuculline-induced enhanced calcium response.

Similarly, stereolithography (SLA) was used to fabricate a 3D scaffold for CNS and the viability of the scaffold was evaluated for regenerative medicine application. Layered linear microchannels were printed using poly(ethylene glycol) diacrylate-gelatin methacrylate (PEGDA-GelMA) and rat E14 neural progenitor cells (NPCs). The 3D scaffold restored the synaptic contacts and significantly improved the functional outcomes. Cyclohexane was used to bond polystyrene fibers to matrix bundle terminals during crosslinking.

Multiphoton excited 3-dimensional printing (MPE-3DP) was employed for the regeneration of myocardial tissue. A layer-by-layer structure was fabricated using GelMA/ sodium 4-[2-(4-morpholino)benzoyl-2-dimethylamino]-butylbenzenesulfonate (MBS) and human hciPSC-derived cardiomyocytes (CMs), endothelial cells (ECs), and smooth muscle cells (SMCs). The crosslinking was performed by photoactivation. The structure promoted electromechanical coupling and improved cell proliferation, vascularity, and cardiac function.

Fused deposition modeling (FDM) and PE/SE bioprinting method were used for complex tissue and organ regeneration. A micro-fluid network heart shape structure was fabricated using polyvinyl alcohol (PVA), agarose, sodium alginate, and platelet-rich plasma and rat H9c2 cells and human umbilical vein endothelial cells (HUVECs). 2% calcium dichloride was used during the crosslinking mechanism. The fabricated structure possessed a valentine heart with hollow mechanical properties and a self-defined height.

SE printing was utilized to fabricate a capillary-like network using collagen type1/ xanthan gum and human fibroblasts and ECs for applications in blood vessels. The fabricated network possessed endothelial networks and sprouting between the fibroblast layers.

Bone, cartilage, and skeletal muscle tissue can be repaired and regenerated using the 3DBP technique. For instance, FDM printing was used to print multifunctional therapeutic scaffolds for the treatment of bone. Filopodial projections were fabricated using polylactic acid (PLA) platform loaded with hyaluronic acid (HA)/ iron oxide nanoparticles (IONS)/ minocycline and human MG-63 and human bone marrow stromal cells (hBMSCs), which improved the osteogenic stimulation of the IONS and HA.

PE/SE method was used to fabricate disks and cuboid-shaped scaffolds using - tricalcium phosphate (TCP) microgel and human fetal osteoblast (hFOB) and bone marrow-derived mesenchymal stem cell (BM-MSC) for bone repair, multicellular delivery, and disease model. The fabricated structures promoted osteogenesis.

PE/SE bioprinting was also utilized to fabricate complex porous layered cartilage-like structures using alginate/gelatin/HA, rat bone marrow mesenchymal stem cells (BMSCs), and cow cardiac progenitor cells (CPCs) for hyaline cartilage regeneration. The CPCs upregulated gene expression of proteoglycan 4 (PRG4), SRY-box transcription factor 9 (SOX9), and collagen II.

PE/SE printing was also used to fabricate multinucleated, highly-aligned myotube structures using polyurethane (PU), poly(-caprolactone) (PCL), and mouse C2C12 myoblasts and NIH/3T3 fibroblasts for in-situ expansion and differentiation of skeletal muscle tendon. The fabricated constructs demonstrated more than 80% cell viability with initial tissue differentiation and development.

SLA bioprinting technique was used to fabricate bi-layered epidermis-like structure using collagen type I, mouse NIH 3T3 fibroblast cells, and human keratinocyte cells for tissue model and engineering. The fabricated constructs effectively imitated the tissue functions.

Similarly, PE was employed to fabricate microporous structures using human amniotic mesenchymal stem cells (AFSCs) and heparin-HA-PEGDA for wound healing. The construct improved the wound closure and reepithelialization, increased extracellular matrix synthesis and vascularization, and prolonged the cell paracrine activity.

PE technique was utilized to prepare a multilayered cornea-like structure using human keratocytes and methacrylated collagen (ColMA)-alginate. The cell viability of the keratocytes decreased from 90% to 83% after printing.

PE/SE bioprinting was utilized to bioprint multilayered liver-like structures using GeIMA and human HepG2/C3A for liver tissue engineering. Similarly, hepatocytes were also bioprinted to fabricate multiple organ precursors with branching vasculature. A small intestine model with improved intestinal function and high cell proliferation was fabricated using caco-2 cell-loaded polyethylene vinyl acetate (PEVA) scaffold.

Spheroids of mesenchymal stem cells (MSCs) and chondrocytes and lung endothelial cells were utilized to fabricate scaffold-free tracheal transplant. After implantation in the rat model, the matured spheroids displayed excellent vasculogenesis, chondrogenesis, and mechanical strength. FDM technique was used to fabricate a glomerular structure for kidneys using human iPSCs and hydrogel and a hollow porous network using poly(lactic-co-glycolic acid (PLGA)/PCL/tumor-associated endothelial cells (TECs) for the urethra.

In in-situ bioprinting, the tissue is directly printed on the specific defect or wound site in the body for regenerative and reparative therapy. This method provides a well-defined structure and reduces the gap between host-implant interfaces. In-situ bioprinting is better than in vitro bioprinting techniques as the patients body, as a natural bioreactor, provides a natural microenvironment.

Several studies have evaluated this technique for tissue regeneration. For instance, PE/SE method was used for skin tissue regeneration in pigs and mice using fibrin/collagen/HA and human fibroblast cells. Skin-laden sheets of consistent composition, thickness, and width were formed upon rapid crosslinking of biomaterial. PE/SE technique was also used for neural tissue regeneration in mice using agarose/CMC/alginate and human iPSCs.

In vitro models provide significant assistance in understanding the mechanism of therapeutics and disease pathophysiology. Recently, in vitro models of human tissues and organs were engineered using 3DBP technology for safety assessment and drug testing.

In the 3DBP of organs and tissues, biomaterials play a crucial role in maintaining cellular viability, providing support, and long-term acceptance. Specifically, bioinks must possess unique properties, such as cell growth promotion and structural stability, that can be optimized for clinical use. Additionally, bioinks must be compatible with printers for high-precision rapid prototyping.

Bioinks fulfilling all of these requirements are yet to be identified. Moreover, managing the time during the bioprinting of the constructs is another major challenge, as the time required to fabricate them is often more than the survival time of cells. A bioreactor platform that supports organoid growth and provides time for tissue remodeling can be used to overcome this challenge. Ethical challenges and issues are also a hurdle since fabricating internal tissues/organs can lead to liability and biosafety concerns.

In the future, 3DBP can provide novel solutions to engineer organs/tissues and revolutionize modern healthcare and medicine if these challenges can be addressed.

More from AZoM: Building Durable and Sustainable Futures with [emailprotected]

Jain, P., Kathuria, H., Dubey, N. Advances in 3D bioprinting of tissues/organs for regenerative medicine and in-vitro models. Biomaterials 2022. https://www.sciencedirect.com/science/article/abs/pii/S0142961222002794?via%3Dihub

Disclaimer: The views expressed here are those of the author expressed in their private capacity and do not necessarily represent the views of AZoM.com Limited T/A AZoNetwork the owner and operator of this website. This disclaimer forms part of the Terms and conditions of use of this website.

Here is the original post:
What New Advances are there in 3D Bioprinting Tissues? - AZoM

The cellular composition and function of the bone marrow niche after allogeneic hematopoietic cell transplantation | Bone Marrow Transplantation -…

Passweg JR, Baldomero H, Chabannon C, Basak GW, de la Cmara R, Corbacioglu S. et al. Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transplant. 2021. https://doi.org/10.1038/s41409-021-01227-8.

Article PubMed PubMed Central Google Scholar

D'Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, et al. Current Use of and Trends in Hematopoietic Cell Transplantation in the United States. Biol Blood Marrow Transplant. 2020;26:e177e182.

Olsson R, Remberger M, Schaffer M, Berggren DM, Svahn B-M, Mattsson J, et al. Graft failure in the modern era of allogeneic hematopoietic SCT. Bone Marrow Transplant. 2013;48:53743.

CAS PubMed Article Google Scholar

Sun Y-Q, He G-L, Chang Y-J, Xu L-P, Zhang X-H, Han W, et al. The incidence, risk factors, and outcomes of primary poor graft function after unmanipulated haploidentical stem cell transplantation. Ann Hematol. 2015;94:1699705.

CAS PubMed Article Google Scholar

de Koning C, Langenhorst J, van Kesteren C, Lindemans CA, Huitema ADR, Nierkens S, et al. Innate immune recovery predicts CD4+ T cell reconstitution after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2019;25:81926.

PubMed Article CAS Google Scholar

Velardi E, Clave E, Arruda LCM, Benini F, Locatelli F, Toubert A. The role of the thymus in allogeneic bone marrow transplantation and the recovery of the peripheral T-cell compartment. Semin Immunopathol. 2021;43:10117.

PubMed Article Google Scholar

de Koning C, Nierkens S, Boelens JJ. Strategies before, during, and after hematopoietic cell transplantation to improve T-cell immune reconstitution. Blood. 2016;128:260715.

PubMed Article CAS Google Scholar

Schofield R. The relationship between the spleen colony-forming cell and the haemopoietic stem cell. Blood Cells. 1978;4:725.

CAS PubMed Google Scholar

Mendelson A, Frenette PS. Hematopoietic stem cell niche maintenance during homeostasis and regeneration. Nat Med. 2014;20:83346.

CAS PubMed PubMed Central Article Google Scholar

Lucas D, Scheiermann C, Chow A, Kunisaki Y, Bruns I, Barrick C, et al. Chemotherapy-induced bone marrow nerve injury impairs hematopoietic regeneration. Nat Med. 2013;19:695703.

CAS PubMed PubMed Central Article Google Scholar

Cao X, Wu X, Frassica D, Yu B, Pang L, Xian L, et al. Irradiation induces bone injury by damaging bone marrow microenvironment for stem cells. Proc Natl Acad Sci USA. 2011;108:160914.

CAS PubMed PubMed Central Article Google Scholar

Pronk E, Raaijmakers MHGP. The mesenchymal niche in MDS. Blood. 2019;133:10318.

CAS PubMed Article Google Scholar

Kong Y, Chang Y-J, Wang Y-Z, Chen Y-H, Han W, Wang Y, et al. Association of an impaired bone marrow microenvironment with secondary poor graft function after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013;19:146573.

PubMed Article Google Scholar

Tikhonova AN, Dolgalev I, Hu H, Sivaraj KK, Hoxha E, Cuesta-Domnguez , et al. The bone marrow microenvironment at single-cell resolution. Nature. 2019;569:2228.

CAS PubMed PubMed Central Article Google Scholar

Baccin C, Al-Sabah J, Velten L, Helbling PM, Grnschlger F, Hernndez-Malmierca P, et al. Combined single-cell and spatial transcriptomics reveal the molecular, cellular and spatial bone marrow niche organization. Nat Cell Biol. 2020;22:3848.

CAS PubMed Article Google Scholar

Spencer JA, Ferraro F, Roussakis E, Klein A, Wu J, Runnels JM, et al. Direct measurement of local oxygen concentration in the bone marrow of live animals. Nature. 2014;508:26973.

CAS PubMed PubMed Central Article Google Scholar

Simsek T, Kocabas F, Zheng J, DeBerardinis RJ, Mahmoud AI, Olson EN, et al. The distinct metabolic profile of hematopoietic stem cells reflects their location in a hypoxic niche. Cell Stem Cell. 2010;7:38090.

CAS PubMed PubMed Central Article Google Scholar

Takubo K, Goda N, Yamada W, Iriuchishima H, Ikeda E, Kubota Y, et al. Regulation of the HIF-1 level is essential for hematopoietic stem cells. Cell Stem Cell. 2010;7:391402.

CAS PubMed Article Google Scholar

Kunisaki Y, Bruns I, Scheiermann C, Ahmed J, Pinho S, Zhang D, et al. Arteriolar niches maintain haematopoietic stem cell quiescence. Nature. 2013;502:63743.

CAS PubMed PubMed Central Article Google Scholar

Mndez-Ferrer S, Michurina TV, Ferraro F, Mazloom AR, MacArthur BD, Lira SA, et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature. 2010;466:82934.

PubMed PubMed Central Article CAS Google Scholar

Katayama Y, Battista M, Kao WM, Hidalgo A, Peired AJ, Thomas SA, et al. Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. Cell. 2006;124:40721.

CAS PubMed Article Google Scholar

Itkin T, Gur-Cohen S, Spencer JA, Schajnovitz A, Ramasamy SK, Kusumbe AP, et al. Distinct bone marrow blood vessels differentially regulate haematopoiesis. Nature. 2016;532:3238.

CAS PubMed PubMed Central Article Google Scholar

Kenswil KJG, Pisterzi P, Snchez-Duffhues G, van Dijk C, Lolli A, Knuth C, et al. Endothelium-derived stromal cells contribute to hematopoietic bone marrow niche formation. Cell Stem Cell. 2021;28:65370.

CAS PubMed Article Google Scholar

Kenswil KJG, Jaramillo AC, Ping Z, Chen S, Hoogenboezem RM, Mylona MA, et al. Characterization of endothelial cells associated with hematopoietic niche formation in humans identifies IL-33 as an anabolic factor. Cell Rep. 2018;22:66678.

CAS PubMed Article Google Scholar

Renders S, Svendsen AF, Panten J, Rama N, Maryanovich M, Sommerkamp P, et al. Niche derived netrin-1 regulates hematopoietic stem cell dormancy via its receptor neogenin-1. Nat Commun. 2021;12:115.

Article CAS Google Scholar

Xu C, Gao X, Wei Q, Nakahara F, Zimmerman SE, Mar J, et al. Stem cell factor is selectively secreted by arterial endothelial cells in bone marrow. Nat Commun. 2018;9:113.

Article CAS Google Scholar

Ludin A, Gur-Cohen S, Golan K, Kaufmann KB, Itkin T, Medaglia C, et al. Reactive oxygen species regulate hematopoietic stem cell self-renewal, migration and development, as well as their bone marrow microenvironment. Antioxid Redox Signal. 2014;21:160519.

CAS PubMed PubMed Central Article Google Scholar

Ding L, Saunders TL, Enikolopov G, Morrison SJ. Endothelial and perivascular cells maintain haematopoietic stem cells. Nature. 2012;481:45762.

CAS PubMed PubMed Central Article Google Scholar

Hooper AT, Butler JM, Nolan DJ, Kranz A, Iida K, Kobayashi M, et al. Engraftment and reconstitution of hematopoiesis is dependent on VEGFR2-mediated regeneration of sinusoidal endothelial cells. Cell Stem Cell. 2009;4:26374.

CAS PubMed PubMed Central Article Google Scholar

Kopp H-G, Avecilla ST, Hooper AT, Shmelkov SV, Ramos CA, Zhang F, et al. Tie2 activation contributes to hemangiogenic regeneration after myelosuppression. Blood. 2005;106:50513.

CAS PubMed PubMed Central Article Google Scholar

Poulos MG, Guo P, Kofler NM, Pinho S, Gutkin MC, Tikhonova A, et al. Endothelial jagged-1 is necessary for homeostatic and regenerative hematopoiesis. Cell Rep. 2013;4:102234.

CAS PubMed PubMed Central Article Google Scholar

Guo P, Poulos MG, Palikuqi B, Badwe CR, Lis R, Kunar B, et al. Endothelial jagged-2 sustains hematopoietic stem and progenitor reconstitution after myelosuppression. J Clin Investig. 2017;127:424256.

PubMed PubMed Central Article Google Scholar

Chen Q, Liu Y, Jeong HW, Stehling M, Dinh VV, Zhou B, et al. Apelin+ endothelial niche cells control hematopoiesis and mediate vascular regeneration after myeloablative injury. Cell Stem Cell. 2019;25:768.e6.

CAS PubMed PubMed Central Article Google Scholar

Hildebrandt GC, Chao N. Endothelial cell function and endothelial-related disorders following haematopoietic cell transplantation. Br J Haematol. 2020;190:50819.

PubMed PubMed Central Article Google Scholar

Poulos MG, Ramalingam P, Gutkin MC, Llanos P, Gilleran K, Rabbany SY, et al. Endothelial transplantation rejuvenates aged hematopoietic stem cell function. J Clin Investig. 2017;127:416378.

PubMed PubMed Central Article Google Scholar

Kim MM, Schlussel L, Zhao L, Himburg HA. Dickkopf-1 treatment stimulates hematopoietic regenerative function in infused endothelial progenitor cells. Radiat Res. 2019;192:5362.

CAS PubMed PubMed Central Article Google Scholar

Ju W, Lu W, Ding L, Bao Y, Hong F, Chen Y, et al. PEDF promotes the repair of bone marrow endothelial cell injury and accelerates hematopoietic reconstruction after bone marrow transplantation. J Biomed Sci. 2020;27:113.

Article CAS Google Scholar

Eissner G, Multhoff G, Gerbitz A, Kirchner S, Bauer S, Haffner S, et al. Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: Protective effect of defibrotide. Blood. 2002;100:33440.

CAS PubMed Article Google Scholar

Kong Y, Wang Y, Zhang YY, Shi MM, Mo XD, Sun YQ, et al. Prophylactic oral NAC reduced poor hematopoietic reconstitution by improving endothelial cells after haploidentical transplantation. Blood Adv. 2019;3:130317.

CAS PubMed PubMed Central Article Google Scholar

Viswanathan S, Shi Y, Galipeau J, Krampera M, Leblanc K, Martin I, et al. Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT) Mesenchymal Stromal Cell committee position statement on nomenclature. Cytotherapy. 2019;21:101924.

CAS PubMed Article Google Scholar

Tormin A, Li O, Brune JC, Walsh S, Schtz B, Ehinger M, et al. CD146 expression on primary nonhematopoietic bone marrow stem cells is correlated with in situ localization. Blood. 2011;117:506777.

CAS PubMed PubMed Central Article Google Scholar

Asada N, Kunisaki Y, Pierce H, Wang Z, Fernandez NF, Birbrair A, et al. Differential cytokine contributions of perivascular haematopoietic stem cell niches. Nat Cell Biol. 2017;19:21423.

CAS PubMed PubMed Central Article Google Scholar

Garca-Castro J, Balas A, Ramrez M, Prez-Martnez A, Madero L, Gonzlez-Vicent M, et al. Mesenchymal stem cells are of recipient origin in pediatric transplantations using umbilical cord blood, peripheral blood, or bone marrow. J Pediatr Hematol/Oncol. 2007;29:38892.

Article Google Scholar

Rieger K, Marinets O, Fietz T, Krper S, Sommer D, Mcke C, et al. Mesenchymal stem cells remain of host origin even a long time after allogeneic peripheral blood stem cell or bone marrow transplantation. Exp Hematol. 2005;33:60511.

CAS PubMed Article Google Scholar

Nicolay NH, Perez RL, Saffrich R, Huber PE. Radio-resistant mesenchymal stem cells: Mechanisms of resistance and potential implications for the clinic. Oncotarget. 2015;6:1936680.

PubMed PubMed Central Article Google Scholar

Alessio N, Del Gaudio S, Capasso S, Di Bernardo G, Cappabianca S, Cipollaro M, et al. Low dose radiation induced senescence of human mesenchymal stromal cells and impaired the autophagy process. Oncotarget. 2015;6:815566.

PubMed Article Google Scholar

Lange SS, Takata K, Wood RD. DNA polymerases and cancer. Nat Rev Cancer. 2011;11:96110.

CAS PubMed PubMed Central Article Google Scholar

Sugrue T, Lowndes NF, Ceredig R. Mesenchymal stromal cells: radioresistant members of the bone marrow. Immunol Cell Biol. 2013;91:511.

CAS PubMed Article Google Scholar

Preciado S, Muntin S, Rico A, Prez-Romasanta LA, Ramos TL, Ortega R, et al. Mesenchymal stromal cell irradiation interferes with the adipogenic/osteogenic differentiation balance and improves their hematopoietic-supporting ability. Biol Blood Marrow Transplant. 2018;24:44351.

PubMed Article Google Scholar

Nicolay NH, Rhle A, Perez RL, Trinh T, Sisombath S, Weber KJ, et al. Mesenchymal stem cells exhibit resistance to topoisomerase inhibition. Cancer Lett. 2016;374:7584.

CAS PubMed Article Google Scholar

Poloni A, Leoni P, Buscemi L, Balducci F, Pasquini R, Masia MC, et al. Engraftment capacity of mesenchymal cells following hematopoietic stem cell transplantation in patients receiving reduced-intensity conditioning regimen. Leukemia. 2006;20:32935.

Excerpt from:
The cellular composition and function of the bone marrow niche after allogeneic hematopoietic cell transplantation | Bone Marrow Transplantation -...

Effects of chitosan nanoparticles loaded with mesenchymal stem cell conditioned media on gene expression in Vibrio cholerae and Caco-2 cells |…

Bacterial culture and growth conditions

A multidrug-resistant clinical strain of V. cholerae stored in the collection of the Bacteriology Department of Tarbiat Modares University, Tehran, Iran, was used. The strain was resistant to tetracycline, ciprofloxacin, chloramphenicol, cotrimoxazole, and trimethoprim. The bacterial culture was performed in 1mL brain heart infusion (BHI) broth (Merck, Germany) at 37C until reaching the log phase. The bacterial suspension concentration was determined by measuring the absorbance at 540nm and comparing it with the standard 0.5 McFarland optical density (OD). According to the growth curve, the bacterial suspension with an OD of 1:0 (~108CFU/mL) was used21.

Bone marrow-derived mesenchymal stem cells (BM-MSCs) and Caco-2 cells were purchased from the Iranian Biological Resource Center and Pasteur Institute of Iran, respectively. BM-MSCs were confirmed by assaying the differentiation of the cells into osteoblasts and adipocytes using an immunohistochemistry (IHC) assay. BM-MSCs were also characterized using the flow cytometry method for CD34, CD45, CD44, and CD73 markers18.

BM-MSCs were cultured in lowglucose Dulbecco's modified Eagles medium (DMEM) (Gibco, USA) supplemented with 10% fetal bovine serum (FBS) (Gibco, USA) and 1% penicillin/streptomycin (Gibco, USA) at 37C in a humidified atmosphere containing 5% CO2. The medium was replaced after every 2days. A total of 5105 cells were seeded in a T75 flask (SPL, Korea) containing 15mL of DMEM supplemented with 10% FBS. When the confluency of the cells was near 90% at passage 2, the medium was replaced with serum-free DMEM. Subsequently, MSC CM was collected and centrifuged at 4000rpm for 30min and finally stored at 80C until use22. According to our previous study, chitosan nanoparticles were synthesized, characterized, and loaded with the supernatant of mesenchymal stem cells23. At all stages of this study, mesenchymal stem cell conditioned media (MSC CM; 1000g), chitosan nanoparticles incorporated with mesenchymal stem cell conditioned media (MSC CM-CS NPs; 1000g+0.05%), and chitosan nanoparticles (CS NPs; 0.05%) were used.

Vibrio cholerae cell suspensions were inoculated (1:100 dilution) into 1mL BHI broth medium containing 0.05% sucrose. The bacterial suspension was inoculated with MSC CM, MSC CM-CS NPs, and CS NPs overnight at 37C to evaluate the expression of biofilm genes. After this time, each well was washed three times with PBS, and adherent cells were harvested to evaluate the expression of biofilm-related genes. PBS and V. cholerae without exposure to the compounds were used as negative and positive controls, respectively. Each assay was performed in triplicate.

Caco-2 cells were cultured in DMEM supplemented with 10% FBS, 1% l glutamine (DNA Biotech, Iran), and 1% penicillin/streptomycin and incubated at 37C with 5% CO2. The culture medium was changed every two days, and when the confluency reached 80%, the cells were passaged. Since cells in monolayer culture with full confluency can form polarized cells while maintaining cell surface molecules, we explored cells at 85% confluency for all experiments24.

Caco-2 cell viability was estimated by the conventional MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay. This was tested to evaluate the viability of Caco-2 cells after the exposure time to bacteria, MSC CM, MSC CM-CS NPs, and CS N. Briefly, 2({10}^{4}) Caco-2 cells per well were seeded into a 96-well plate and cultured for 24h at 37C. The medium was removed, and the cells were exposed to bacterial suspension (10 bacteria per epithelial cell; MOI: 10), MSC CM, MSC CM-CS NPs, and CS NPs separately for 24h. To assess cytotoxicity, a separate test was also performed for 72h. After these times, the medium was removed, and MTT solution was added for 3h at 37C. Then, the formazan crystals formed in cells were dissolved in 100L of dimethyl sulfoxide (Sigma Aldrich, USA). The resulting purple solution was measured using an ELISA reader (OD 540nm) (800 TS, BioTek, Winooski, Vermont, USA). Each assay was performed in triplicate25.

For this purpose, five groups were designed: (i) untreated Caco-2 cells (negative control); (ii) Caco-2 cells incubated with V. cholerae (MOI: 10-positive control); (iii) Caco-2 cells+V. cholerae+MSC CM; (iv) Caco-2 cells+V. cholerae+CS NPs; and (v) Caco-2 cells V. cholerae+MSC CM-CS NPs. Caco-2 cells were cultured in 96-well microplates until they reached 80% confluence. Before treatment, cells were washed three times with PBS. Then, the cells were infected with V. cholerae for 1h, and the extracellular bacteria and medium was removed and replaced with DMEM-free compounds, including 100L of MSC CM, MSC CM-CS NPs, and CS NPs, for 18h at 37C. After this time, the supernatant were removed, and then Caco-2 cells were used for total RNA extraction. Each test was performed in triplicate.

Total RNA from bacteria and Caco-2 cells was extracted using an RNA Miniprep Super Kit (Bio Basic, Canada) according to the manufacturers recommendations. The RNA was assayed by absorbance at OD260/280. Samples with a ratio of 1.82.0 were used for cDNA synthesis using Yekta Tajhiz Azma, Iran. According to the protocol, template RNA (5L), random primer (0.5L), and DEPC-treated water (7.5L) were mixed, centrifuged briefly, and incubated for 5min at 70C. Then, 5 first strand buffer (4L), dNTPs (1L), RNase 40U/L (0.5L), and M_MLV (1L) were mixed and incubated for 60min at 42C, and the reaction was terminated by heating for 5min at 70C. The cDNA samples were stored at 20C until use in the following experiment.

Conventional SYBR Green-based real-time PCR was used for target gene quantification. Real-time PCR was performed by using 10L 5 Real-time PCR Master Mix (Biomake, Houston, TX, USA), 1L of each primer (Table 1), 2L of cDNA, and 6L of distilled water in a total reaction volume of 20L in Stratagene Mx3000P real-time PCR system (Stratagene, La Jolla, CA). 16S rRNA was used as an endogenous control to normalize the expression levels of target genes of V. cholerae. Beta-actin was also utilized as an internal control to normalize the expression levels in RNA samples from Caco-2 cells. The CT of each sample was measured (CT targetCT reference). We used Caco-2 cells not treated as a calibrator, and the CT method was used to determine the difference between treated cells and the control. The fold change of gene expression level was calculated using the comparative CT (2CT).

The data were analyzed by using GraphPad Prism version 6 using one-way ANOVA and Bonferroni post hoc test. P value<0.05 was accepted as significant. The results of replications were also evaluated as the meanstandard deviation (SD).

The study was reviewed and approved by the Medical Ethics Committee of Tarbiat Modares University (Code: IR.MODARES.REC.1398.060). All methods were also carried out in accordance with the guidelines and regulations related to the committee.

See the original post here:
Effects of chitosan nanoparticles loaded with mesenchymal stem cell conditioned media on gene expression in Vibrio cholerae and Caco-2 cells |...

Cord Stem Cell Banking Market Gross Margins, Application, Growth,Size, Share, Trends,Top Key Players with Strategies and Forecast Designer Women -…

Global Cord Stem Cell Banking Marketreport aids businesses in gaining knowledge about what is already there in the market, what market looks forward to, the competitive background and steps to be followed for outdoing the rivals. Effortlessness maintained in research method and application of best tools and techniques makes this market research report an outstanding. The report is bifurcated into several attributes which include manufacturers, region, type, application, market status, market share, growth rate, future trends, market drivers, opportunities, challenges, emerging trends, risks, entry barriers, sales channels, and distributors which are again detailed in the universal A business report as required to describe the topic and provide maximum information for better decision making.

The key research methodology employed here by DBMR team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary validation. It has been assured that this business report makes available absolute knowledge and insights to the clients about the new regulatory environment which suits to their organization. The winningCord Stem Cell Banking Marketbusiness report helps clients recognize new opportunities and most important customers for their business growth and increased revenue.

With the resourceful use of technology, innovative applications, and expertise,Cord Stem Cell BankingMarket analysis report is built which successfully manages large and complex market data tables. The market report is produced based on the market type, organization size, availability on-premises, end-users organization type, and the availability in areas such as North America, South America, Europe, Asia-Pacific and Middle East & Africa. Not to mention, gathered market data and information is represented very well in the persuasive Cord Stem Cell Banking Market report with the help of graphs, charts or tables to simplify the flow for better user understanding. Market share analysis and key trend analysis are the two other major success factors of this influential market survey report.

Get a Sample PDF of the Cord Stem Cell Banking Market report https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-cord-stem-cell-banking-market

The cord stem cell banking market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to grow at a CAGR of 22.2% in the above-mentioned forecast period. Increase in the number of parents storing their childs cord blood drives the cord stem cell banking market.

Cord stem cells banking is defined as the storing of the cord blood cell contained in the umbilical cord and placenta of a newborn child. This cord blood contains the stem cells which can be used in future to treat disease such as leukemia, thalassemia, autoimmune diseases, and inherited metabolic disorders, and few others.

Global Cord Stem Cell Banking MarketScenario

According to Data Bridge Market Research the market for cord stem cell banking is booming with the rising expenditure in the healthcare solutions. The increment in the novel advancement for creating good and efficient drugs to cure unmet medical challenges for the betterment of public and patients health will deliver a strategic business growth for cord stem cell banking market globally.

The rising demand of cord stem cells by pharmaceuticals enterprises has arranged an ascending array of rise in the cord stem cell banks. This significant germination will be backed by the collection placentas of new born babies after their delivery. The stem cells procured from this source are capable of regenerating advanced cells. They help in transplantation of hematopoietic stem cell, the rate of transplantation is high so thus the requirement. These inputs yields in the graphical success of cord stem cell banking market will be visible in the forthcoming period of 2019 to 2026. Few of the factors will stand in between to hinder the market growth such as high end cost of the preservation and storage of cord stem blood cells, whereas the lower rate of familiarity among the pregnant population will affect its growth.

Now the question is which are the other regions intuitive is targeting? Data Bridge Market Research has forecasted a large growth in North America due to large healthcare infrastructure and leading investment in the cord blood cells research to generate stem cells.

For more analysis on the cord stem cell banking market request for a briefing with our analystshttps://www.databridgemarketresearch.com/reports/global-cord-stem-cell-banking-market

Cord Stem Cell Banking MarketDevelopment and Acquisitions in 2019

In September 2019, a notable acquisition was witnessed between CBR and Natera. This merger will develop the new chances of growth in the cord stem blood banking by empowering the Nateras Evercord branch for storing and preserving cord blood. The advancement will focus upon research and development of the therapeutic outcomes, biogenetics experiment, and their commercialization among the global pharma and health sector.

Cord Stem Cell Banking MarketScope

Cord Stem Cell Banking Marketis segmented on the basis of countries into U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

All country based analysis of the cord stem cell banking marketis further analyzed based on maximum granularity into further segmentation. On the basis of storage type, the market is segmented into private banking, public banking. On the basis of product type, the market is bifurcated into cord blood, cord blood & cord tissue. On the basis of services type, the market is segmented into collection & transportation, processing, analysis, storage. On the basis of source, market is bifurcated into umbilical cord blood, bone marrow, peripheral blood stem, menstrual blood. On the basis of indication, the market is fragmented into cerebral palsy, thalassemia, leukemia, diabetes, autism.

Cord stem cell trading is nothing but the banking of the vinculum plasma cell enclosed in the placenta and umbilical muscle of an infant. This ligament plasma comprises the stem blocks which can be employed in the forthcoming time to tackle illnesses such as autoimmune diseases, leukemia, inherited metabolic disorders, and thalassemia and many others.

To Gain More Insights into the Market Analysis, Browse Summary of the Research Report@https://www.databridgemarketresearch.com/reports/global-cord-stem-cell-banking-market

Increased acceptance of stem cell therapeutics is the vital factor escalating the market growth, also rise in the new applications of stem cells indiseasetreatment, rise in the spending on the management of chronic diseases, rise in the growth in awareness about stem cell therapeutics and increase in the mergers and acquisitions by prominent players are the major factors among others driving the cord stem cell banking market. Moreover, rise in the technological advancements and modernization in the healthcare devices and risingresearch and developmentactivities in the healthcare sector will further create new opportunities for cord stem cell banking market in the forecasted period of 2021-2028.

However, high operating cost of stem cell therapeutics and lack of awareness in many developing economies are the major factors among others which will obstruct the market growth, and will further challenge the growth of cord stem cell banking market in the forecast period mentioned above.

The cord stem cell banking market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cord stem cell banking market contact Data Bridge Market Research for anAnalyst Brief, our team will help you take an informed market decision to achieve market growth

Key Market Competitors Covered in the report

CBR Systems, IncCordlifeCells4Life Group LLPCryo-Cell International, Inc.Cryo-Save AGLifecellStemCyte India Therapeutics Pvt. LtdViacordSMART CELLS PLUS.Cryoviva IndiaGlobal Cord Blood CorporationNational Cord Blood ProgramVita 34, ReeLabs Pvt. Ltd.Regrow Biosciences Pvt. Ltd.Americord Registry LLC.New York Blood CenterMaze Cord BloodAABBStem Cell CryobankNew England Cryogenic Center, Inc.

Cord Stem Cell Banking MarketScope and Market Size

The cord stem cell banking market is segmented on the basis of storage type, product type, service type, source and indication. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

On the basis ofstorage type, the cord stem cell banking market is segmented into private banks, hybrid banks and public banks.

Based onproduct type, the cord stem cell banking market is segmented into cord blood, cord blood and cord tissue.

Based on service type, the cord stem cell banking market is segmented into collection & transportation, processing, analysis and storage.

Based on source, the cord stem cell banking market is segmented into umbilical cord blood, bone marrow, peripheral blood stem and menstrual blood

The cord stem cell banking market is also segmented on the basis of role of administration into cerebral palsy, thalassemia, leukemia, diabetes and autism.

Browse the complete table of contents at Cord Stem Cell Banking Market https://www.databridgemarketresearch.com/toc/?dbmr=global-cord-stem-cell-banking-market

Cord Stem Cell Banking MarketCountry Level Analysis

The cord stem cell banking market is analysed and market size insights and trends are provided by country, storage type, product type, service type, source and indication as referenced above.

The countries covered in the cord stem cell banking market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the cord stem cell banking market due to rise in the presence of major market participants in the US, ongoing approval of stem cell lines for disease treatment, and increasing awareness among citizens in this region. Asia-Pacific is the expected region in terms of growth in cord stem cell banking market due to rise in the older population along with as surge in prevalence of chronic diseases, and rising per capita healthcare expenditure in this region.

The country section of the cord stem cell banking market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure growth Installed base and New Technology Penetration

The cord stem cell banking market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipments, installed base of different kind of products for cord stem cell banking market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the cord stem cell banking market. The data is available for historic period 2010 to 2019.

Key Pointers Covered in the Cord Stem Cell Banking MarketIndustry Trends and Forecast

Market SizeMarket New Sales VolumesMarket Replacement Sales VolumesMarket Installed BaseMarket By BrandsMarket Procedure VolumesMarket Product Price AnalysisMarket Healthcare OutcomesMarket Cost of Care AnalysisMarket Regulatory Framework and ChangesMarket Prices and Reimbursement AnalysisMarket Shares in Different RegionsRecent Developments for Market CompetitorsMarket Upcoming ApplicationsMarket Innovators Study

Key Pointers CoveredMarket SizeMarket GrowthTop to Bottom Market AnalysisMarket SegmentedRecent Developments for Market CompetitorsRecent Market Value for Different CountriesMarket Value and OverView of this MarketCompany Profiling of Players of this Market

Why buy this report?

The report offers a comprehensive evaluation of the Global & Regional Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.The report includes an in-depth market analysis using Porters 5 forces model and the Ansoff Matrix. In addition, the impact of Covid-19 on the market is also featured in the report.The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.The report also contains the competitive analysis using Positioning Quadrants, the analysts Proprietary competitive positioning tool.

Market highlights:Assessment of the marketPremium InsightsCompetitive LandscapeCOVID Impact AnalysisHistoric Data, Estimates and ForecastCompany ProfilesGlobal and Regional Dynamics

Key Questions Answered in the Market Report

How did the COVID-19 pandemic affect the reception of by different statistical surveying and life sciences organizations? What is the viewpoint for the effective market during the conjecture time frame? What are the key patterns affecting the effect market? How might they impact the market in short-, mid-, and long-haul length? What is the end clients insight toward? What are the key variables affecting the effect market? What will be their effect in the short-, mid-, and long-haul term? What are the key open doors regions in the effect market? What is their possible in short-, mid-, and long haul length? What are the key systems taken on by organizations in the effect market? What are the key application regions of the effect market? Which application is supposed to hold the most noteworthy development potential during the gauge time frame? What is the favored sending model for the effect? What is the development capability of different arrangement models present on the lookout? Who are the key end clients of this statistical surveying quality? What is their separate offer in the effect market? Which territorial market is supposed to hold the most noteworthy development potential in the effect market during the conjecture time frame? Which are the central members in the effect market?

Report Coverage-The report involves data triangulation based on top-down and bottom-up approaches.The report contains details on revenues, growth rate, strategies, etc.The report highlights market and technological trends, new product developments, etc.The report elucidates the data gathered from interviews with reputed stakeholders such as product managers, C-level executives, among others, operating in the market.The report also highlights the impact of COVID-19 and suggests measures and strategies to grow in the approaching years.

Top DBMR Healthcare Reports:

https://www.einpresswire.com/article/574127712/internet-of-medical-things-iomt-market-share-size-growth-revenue-technologies-top-leaders-forecast-to-2028

https://www.einpresswire.com/article/574124944/clinical-trials-market-size-share-growth-segment-trends-developing-technologies-opportunities-forecast-to-2029

https://www.einpresswire.com/article/574118495/ehealth-market-by-emerging-trends-business-strategies-technologies-revenue-to-grow-at-cagr-of-23-00-by-2029

https://www.einpresswire.com/article/574106412/u-s-psychedelic-drugs-market-is-expected-to-reach-usd-9818-68-million-by-2029-by-source-drug-application-treatment

https://www.einpresswire.com/article/574288865/aesthetic-devices-market-grow-at-a-cagr-of-10-30-and-is-expected-to-reach-usd-28-865-17-million-by-2029

https://www.einpresswire.com/article/574277868/probiotics-market-size-share-trends-business-challenges-opportunities-industry-trends-key-players-and-revenue

https://www.einnews.com/pr_news/574565434/psychedelic-drugs-market-by-source-type-drugs-application-size-share-trends-growth-regional-overview-forecast

https://www.einnews.com/amp/pr_news/574553655/europe-digital-therapeutic-dtx-market-by-product-and-service-type-application-size-share-trends-and-technology

https://www.einpresswire.com/article/574545729/pharmaceutical-logistics-market-size-share-growth-segment-trends-developing-technologies-and-top-leading-company

https://www.einpresswire.com/article/574696424/hospital-staffing-market-by-staffing-service-type-trends-growth-is-expected-to-reach-usd-56-32-billion-by-2029

https://www.einpresswire.com/article/574713353/chimeric-antigen-receptor-car-t-therapy-treatment-market-by-therapeutic-application-processes-drugs-size-share

Read the original:
Cord Stem Cell Banking Market Gross Margins, Application, Growth,Size, Share, Trends,Top Key Players with Strategies and Forecast Designer Women -...

Jasper Therapeutics Announces Annual Virtual Stockholders Meeting to be Held on Thursday, June 23, 2022 – GuruFocus.com

REDWOOD CITY, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. ( JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced that its 2022 Annual Meeting of Stockholders will be held on Thursday, June 23, 2022, at 10:00 a.m. Pacific Time. This years meeting is a virtual stockholder meeting conducted exclusively via live audio webcast on the Internet at https://www.cstproxy.com/JasperTherapeutics/2022. As described in the proxy materials previously distributed, stockholders of record at the close of business on April 26, 2022 are entitled to participate and vote at the 2022 Annual Meeting. To participate, stockholders will need to enter the 12-digit control number included in the proxy materials delivered to such stockholders.

Information about the virtual meeting webcast and instructions for how stockholders can participate in the 2022 Annual Meeting are included in the definitive proxy statement filed with the Securities and Exchange Commission on April 29, 2022 and are available on the InvestorsFinancials & Filings section of Jasper Therapeutics website at http://www.jaspertherapeutics.com or the website for the 2022 Annual Meeting at https://www.cstproxy.com/JasperTherapeutics/2022.

About Jasper Therapeutics, Inc.

Jasper Therapeutics, Inc. is a biotechnology company focused on the development of novel curative therapies based on the biology of the hematopoietic stem cell. The company is advancing two potentially groundbreaking programs. JSP191, an anti-CD117 monoclonal antibody, is in clinical development as a conditioning agent that clears hematopoietic stem cells from bone marrow in patients undergoing hematopoietic cell transplantation. It is designed to enable safer and more effective, and potentially curative, allogeneic hematopoietic cell transplants and gene therapies. A clinical study of JSP191 as a novel, disease-modifying, therapeutic for patients with lower risk MDS is also planned to begin in 2022. In parallel, Jasper Therapeutics, Inc. is advancing its preclinical mRNA hematopoietic stem cell grafts platform, which is designed to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. Both innovative programs have the potential to transform the field and expand hematopoietic stem cell therapy cures to a greater number of patients with life-threatening cancers, genetic diseases and autoimmune diseases than is possible today. For more information, please visit us at jaspertherapeutics.com.

Contacts:

John Mullaly (investors)LifeSci Advisors617-429-3548[emailprotected]

Jeet Mahal (investors)Jasper Therapeutics650-549-1403[emailprotected]

More:
Jasper Therapeutics Announces Annual Virtual Stockholders Meeting to be Held on Thursday, June 23, 2022 - GuruFocus.com

Global Rheumatoid Arthritis Stem Cell Therapy Market 2022 Swot Analysis by Top Key Vendors, Demand And Forecast Research to 2028 Designer Women -…

MarketQuest.biz has announced the addition of new research titled Global Rheumatoid Arthritis Stem Cell Therapy Market from 2022 to 2028, which encompasses regional and global market data and is predicted to generate attractive valuation.The Rheumatoid Arthritis Stem Cell Therapy research covers market drivers, opportunities, limiting factors, and barriers. It provides a quantitative market study based on annual reports, product literature, industry announcements, and other sources.

The report explains the market definition, classifications, applications, engagements, and global Rheumatoid Arthritis Stem Cell Therapy industry trends are.It gives a realistic picture of the current market position incorporating original and predicted market estimates.The report gives a thorough analysis of their product portfolios to investigate the products and applications they focus on while working in the worldwide Rheumatoid Arthritis Stem Cell Therapy market. The report offers valuable suggestions to new just as set up players of the market.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketquest.biz/sample-request/121261

In order to improve industrial planning, data points such as flow patterns, openings, drivers, limits, and statistics are acquired from trusted sources. The data and numbers in the research report have been provided comprehensively, using graphical and pictorial representations to understand the market better.Further when datais synthesised, statistical analysis takes place. Several processes, including screening, integration, and data extrapolation, must be performed prior to data validation.

The product types covered in the report include:

The application types covered in the report include:

The countries covered in the market report are:

The key and emerging market players in the global market include:

ACCESS FULL REPORT: https://www.marketquest.biz/report/121261/global-rheumatoid-arthritis-stem-cell-therapy-market-2022-by-company-regions-type-and-application-forecast-to-2028

Significance of The Report gives the idea about thebroad and precise understanding, industry drivers and challenges affecting the industry growth, planning the business strategies and factors leading to the market development, and evaluating the market competition and planning

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketquest.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on 1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: 1-201-465-4211Email: sales@marketquest.biz

More here:
Global Rheumatoid Arthritis Stem Cell Therapy Market 2022 Swot Analysis by Top Key Vendors, Demand And Forecast Research to 2028 Designer Women -...

Stem Cell Transplant the only curative treatment for Sickle cell Disease – NewsPatrolling

World Sickle Cell Day 2022:

Bangalore, June 16, 2022: There are as many as 2.5 million carrier of the gene (Hemoglobin AS) in India that can lead to sickle cell disease, with more than 1,25,000 actual patients spread across the country, with a much higher incidence in the tribal belt of the country. Sickle cell disease is associated with a significant risk of morbidity and premature mortality, especially among children. While in the west, a child receiving comprehensive care in high-resource settings has an estimated 99% survival into adulthood. However, in India, according to an ICMR study, about 20 per cent of children with sickle disease died by the age of two, and 30 per cent children with Sickle Cell Disease die before they reach adulthood.

Dr. Biju George, Professor & Head, Department of Haematology at CMC Vellore, People with Sickle Cell Disease, may beat a risk of progressive organ damage, impaired quality of life, considerable morbidity in childhood, and risk of premature mortality in adulthood [median survival of 58 years]. Sickle Cell disease patients who are undergoing regular life-long blood transfusions, have the best chance of survival and cure with a blood stem cell transplant. This transplant can come from a sibling or a family member. However, there is only a 30% chance of finding a matched sibling donor in the same family. The remaining 70% patients look for a matching donor through a stem cell registry or donor center- a database of voluntary donors between the age group of 18 to 50 years.

Dr. Govind Eriat Nair, Consultant Hematology Hemato-Oncology and Bone Marrow Transplant Gleneagles Global BGS Hospital, Bengaluru, If there is a fully HLA matched donor in the family, there is a 90-95% chance of cure with higher cure rates in younger children of below 12 years of age. However, due to underrepresentation of Indians in the global donor data pool, patients are unable to find a match on time. Also, the awareness about the disease is less, need of the hour is to raise the social awareness about this disease. Genetic counseling and newborn screening are the way forward. Effects of endogamy, consanguinity and role prenatal counseling needs to be addressed in primary screening.

DKMS BMST Foundation India is a non-profit organization dedicated to the fight against blood cancer and other blood disorders, such as thalassemia and sickle cell disease. The organization aims to give every blood disorder patient in need a second chance at life.

To mark World Sickle Cell Day, Patrick Paul, CEO, DKMS BMST Foundation India said, Sickle cell has variance and only the severe form needs a stem cell transplant. An early transplant can help patient with severe Sickle cell disease from organ damage. With rising cases in India, it is the need of the hour that stem cell transplants are made available to more patients to save lives. But due to the misconceptions and lack of awareness about blood stem cell donation, Indians are highly underrepresented in the global donor pool. This situation can only be changed by recruiting many more potential blood stem cell donors from the Indian ethnicity.

The success of a stem cell transplant depends of donors HLA (Human Leukocyte Antigen) matching the patient. The bodys immune system has proteins known as HLA to distinguish cells that belong to the body from those that do not. DKMS-BMST helps in unrelated donor transplant process which includes enrolling and counselling the donors, get their HLA typing done, facilitate search of the donors and later facilitate the blood stem cell collection and the transplant. So, far DKMS-BMST has registered over 60,000 potential donors and have helped 60 patients with second chance at life.

Register as a potential blood stem cell donor:

Healthy individuals between 18-50 years of age can register at: dkms-bmst.org/register

All it takes is five minutes of your time and a simple 3 step process:

Step 1: Visit the site, fill up an online form and you will receive a DIY swab kit at home.

Step 2: Once you receive the swab kit, fill out the consent form and take a tissue sample from the inside of your cheeks with 3 cotton swabs provided in the kit.

Step 3: Send back your swab sample in the pre-paid envelope provided.

DKMS laboratory will then analyze your tissue type and your details will be available in the global search for blood stem cell donors. If you do come up as a suitable donor, DKMS-BMST will get in touch with you straight away. Once you come up as a match, blood stem cells will be obtained from the bloodstream using a procedure called Peripheral Blood Stem Cell Collection, which is similar to a blood donation wherein only your stem cells are taken. This is a safe, non-surgical outpatient procedure.

Read more:
Stem Cell Transplant the only curative treatment for Sickle cell Disease - NewsPatrolling

STEMTECH CORPORATION CHAIRMAN AND CEO CHARLES ARNOLD RECEIVES GLOBAL EAGLES BUSINESS LEADER OF THE YEAR AWARD – StreetInsider.com

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

MIRAMAR, FL, June 16, 2022 (GLOBE NEWSWIRE) -- Stemtech Corporation (Stemtech) (OTCQB: STEK), an innovative nutraceutical company and a pioneer in the field of stem cell nutrition, announced today that Charles Arnold, Stemtechs Chairman and CEO, has received the Global Eagles Business Leader of the Year award.

The award was presented at a ceremony in Fort Lauderdale, Florida by Global Eagles International Chairman the Honorable Randy Avon. The Global Eagles is a group of diplomats, investment bankers, CEOs, University Presidents, investors and top international executives who gather regularly to network, present global projects to a group of seasoned peers, and to promote best leadership practices.

I am truly honored to receive the Global Eagles Business Leader of the Year award, said Chuck Arnold, Chairman and CEO of Stemtech. The Global Eagles community is a distinguished group that includes top leaders in business, the investment community, government and academia. The impact that this organization and its members have had on international development and infrastructure is hard to overstate. I continue to enjoy the camaraderie and friendship of fellow Global Eagles members, and I look forward to being a member for many years to come.

About Stemtech Corporation

Stemtech Corporation, a leading nutraceutical company with a direct sales distribution model, was founded on April 18, 2018, after acquiring the operations from its predecessor Stemtech International, Inc. which was founded in 2005. From 2010 through 2015, Stemtech International, Inc., was recognized four separate times on the Inc. 5000 Fastest-Growing Companies list. In 2018, the Company underwent an extensive executive reorganization, and continued operations under new leadership. Stemtech specializes in creating products and formulas that are patent-protected in the U.S. and in select international markets. The Companys patented formulas help the release, circulation and migration of the bodys adult stem cells from its bone marrow. The Company markets its products under the following brands: RCM System, stemrelease3, Stemflo MigraStem, OraStem (Oral Health Care), and D-Fuze (EMF Blocker). Its products are all-natural and plant-based and manufactured under cGMP (Current Good Manufacturing Practices) under the auspices of the Dietary Supplement Health and Education Act (DSHEA). For more information, please visit http://www.stemtech.com.

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q Report filed onMay 16th, 2022. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Stemtech Corporation which are condoned by the Company must emanate from the Company itself and bear our name as its Source.

For Further Information, Contact:

Investor Relations: Frank J. Pena, 908-675-0581,

[emailprotected]

Read the original here:
STEMTECH CORPORATION CHAIRMAN AND CEO CHARLES ARNOLD RECEIVES GLOBAL EAGLES BUSINESS LEADER OF THE YEAR AWARD - StreetInsider.com

BioRestorative Therapies Announces Clinical Site Initiation for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD) -…

First Site Will Enroll First Patient in the Clinical Study

MELVILLE, NY., June 13, 2022 (GLOBE NEWSWIRE) BioRestorative Therapies, Inc. (the Company or BioRestorative) (NASDAQ: BRTX),a clinical stage company focused on stem cell-based therapies, today announced site initiation for its Phase 2 clinical trial targeting chronic lumbar disc disease (cLDD). The Denver Spine and Pain Institute is the first clinical site to be initiated. Additional selected sites are expected to be initiated in 2022.

BioRestoratives Phase 2 trial is a double-blind controlled, randomized study to evaluate the safety and preliminary efficacy of a single dose intradiscal injection of the Companys autologous investigational stem cell-based therapeutic, BRTX-100. A total of up to 99 eligible patients will be randomized at up to 15 centers in the United States to receive either the investigational drug (BRTX-100) or control in a 2:1 fashion.

Currently there are no approved, cell-based therapies for cLDD. While there is encouraging data that suggests that patients with cLDD could benefit from autologous stem cell transplants, the low oxygen micro-environment of the disc makes cell-based therapies challenging. BRTX-100 is manufactured under low oxygen conditions and engineered to survive this environment, said Scott Bainbridge, M.D., Principal Investigator for the BRTX-100 trial at The Denver Spine and Pain Institute. Positive proof-of-concept data in this trial could be disruptive and support the potential applicability of BRTX-100 to other spine and musculoskeletal disorders where low oxygen micro-environments are found.

We are pleased to initiate the first of several sites across the United States that will be enrolling for the trial, said Lance Alstodt, Chief Executive Officer of BioRestorative Therapies. Our sites have been carefully reviewed and selected and have clinical expertise in treating patients who could potentially benefit from BRTX-100. We look forward to working with the principal investigators and their clinical trial teams.

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders:

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Companys latest Form 10-K filed with the Securities and Exchange Commission and other public filings. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

CONTACT:Email:ir@biorestorative.com

Read more:
BioRestorative Therapies Announces Clinical Site Initiation for the Company's Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD) -...

Surgery gives teen opportunity to help other kids with cancer – Houston Chronicle

For every procedure Hallie Barnard has undergone at MD Anderson, she receives a bead. The yellow ones symbolize each night in the hospital. The ones that glow in the dark represent radiology appointments.

Theyre for every poke, every wound cleaning, every physical therapy appointment, the 13-year-old said.

MD Anderson launched its Beads of Courage program in 2008 so young patients could document their journeys through cancer treatment. Collecting colorful strings of beads also provides some incentive to show up at dreaded doctor appointments.

Hallie has more than 350 feet of beads.

They symbolize everything that Ive gone through in the past four years, the Denton resident said.

Still, Hallie is less concerned about her own struggles through osteosarcoma, a cancer that begins in the bones, than she is with shining a light on the challenges other children face.

Every time I show people my beads, it dawns on them that children are going through so much, she said. And there are children with longer beads than I have.

According to the American Childhood Cancer Organization, about 15,780 children are diagnosed with cancer in the U.S. each year.

Their studies indicate 1 in 285 children will be diagnosed with cancer before their 20th birthday and that cancer is the leading cause of death for children between the ages of 4 and 14 in the country.

Children are dying of cancer at astonishing rates, Hallie said.

Regardless, she said, childhood cancer research is underfunded. Less than 4 percent of the federal budget for cancer research is dedicated to its study, according to the Childrens Cancer Research Fund, a national nonprofit.

I dont want any of my friends to die anymore, Hallie said. I want to show them that I am there for them. I am their voice. I can speak for those who cannot speak for themselves.

Hallies Heroes, the nonprofit she started with her parents, Elyse and Jesse Barnard, helps fund childrens cancer research.

But thats not how it began. The organization was founded to inspire individuals to register as bone marrow donors. Because, at the time, Hallie was facing another seemingly insurmountable challenge finding a match for herself.

Hallie was diagnosed with Diamond-Blackfan anemia when she was 13 months old.

Your bone marrow is basically what makes your red blood cells, she said. And with DBA, that fails to happen, Hallie said.

Elyse said her daughter did not seem to be growing normally or hitting milestones at the right time during her first year of life.

Our pediatrician would tell me everything was OK, she said. As a first-time mom, we tend to worry about everything, but I knew that something was wrong.

That fear was validated when Hallie went for her 12-month checkup. A blood test revealed low levels of hemoglobin, and she was admitted to the hospital.

Diagnostics pointed to Diamond-Blackfan anemia but doctors were still skeptical due to the rarity of the disease, Elyse said.

In the end, Hallie had a diagnosis. But treatment options were even more elusive.

Only five to seven babies per million have Diamond-Blackfan anemia, according to St. Judes Research Hospital.

Blood transfusions and steroids can be used to manage symptoms, but both take a toll on the body, Elyse said.

Stem cell transplants offer the only possible cure. The issue is finding a donor.

Theres just a 1 percent chance of finding a match for bone marrow transplants, Hallie said.

Her family began looking and moved from Virginia to Texas, after learning that Dallas had one of the four hospitals in the U.S. specializing in the disorder.

Out of the Barnards search for donors, Hallies Heroes was born.

In the search for her own bone marrow donor, other matches were made. So far, there have been 184 and the organization has inspired more than 8,000 people to join the bone marrow registry.

To its mission, Hallies Heroes added funding for Diamond-Blackfan anemia research and covering medical bills.

Hallie found her own match for a bone marrow transplant when she was 9. The procedure was scheduled the following year, 2018.

She was in the hospital for 60 days, kept in isolation for the duration to protect her fragile immune system, which was wiped out by chemo.

After 100 days, the bone marrow transplant is usually considered fully integrated, Elyse said.

You basically do a happy dance, because you have a new immune system, she said. We thought we were in the clear.

But at 120 days, Hallie had a new symptom.

I started getting horrible pains in my leg, she said. We found a small bump, the size of a mosquito bite.

The growth was right above her left knee. Doctors told her to draw a circle around it to see if it grew.

In a week, it had doubled, Hallie said.

Diagnostics revealed the bump was indeed a tumor.

In March 2019, Hallie was diagnosed with osteosarcoma, a bone cancer that develops most often in children and young adults.

Hallie was presented with a few different choices. She could opt for an amputation or limb salvage surgery to remove diseased bone and replace it with a metal implant or a bone graft, called at allograft, from another person.

We wanted to get a second opinion, Hallie said. Our doctor said, I studied under this amazing woman, Dr. Lewis. Yall should go to MD Anderson.

Dr. Valerae O. Lewis serves as the inaugural chair of orthopedic oncology at the hospital. In fact, she created the Department of Orthopedic Oncology in 2014.

The Barnards made an appointment to see her in mid-April 2019.

Data from MD Anderson shows that between 800 and 900 cases of osteosarcoma are diagnosed annually in the U.S. About half of these are children and teens.

Lewis presented Hallie with three options. You can do an amputation, she began.

Historically, that was the only choice available to remove the tumor completely. But now there are additional options limb-salvaging surgery and rotationplasty, Lewis said.

Limb-salvaging surgery can be performed if the cancer has not metastasized.

Limb-salvage is a great option, because it gives kids the ability to keep their legs, Lewis said. But it does take a toll.

Patients activity levels are restricted and additional operations are needed down the road, probably every 15 to 20 years.

The third option, a rotationplasty, removes the tumor along with the middle part of the leg and the knee. The surgeon then rotates the lower leg 180 degrees before reattaching it to the thigh.

Its like an amputation, but we create a new knee, Lewis said.

Rotationplasty allows patients to be higher functioning. Its easier to walk, Lewis said. You can bike, skate and swim. Everything you need a knee for, you can do.

Hallie chose rotationplasty. Surgery was scheduled for late June 2019, and she had chemo before and after surgery.

She was 11 at the time and had complications while healing, including infections. She needed a wound vacuum for about 11 months. When Hallie finished chemo in 2020 in Fort Worth, her bones had not yet fused.

Then, Dr. Lewis came up with a genius idea, Hallie said.

Lewis inserted a titanium rod into the nonhealing site to help.

Hallie said that Lewis restored her confidence.

Theres a point when a patient gives up. And theres also a point when a doctor gives up. She said that she had not given up on my leg yet, Hallie recalled.

After rotationplasty, a prosthesis is worn, and patients have to relearn how to walk.

Even though the ankle now functions as the knee, it is entirely different from the typical configuration, Lewis said.

The foot fits into the prosthesis, she said. And one needs to remember that it is a functional foot interfacing with the prosthesis.

The toes can provide balance and aid in powering the prosthesis, Lewis added. The plantar surface also allows for bearing weight.

Hallie was at MD Anderson for about seven months, working on both physical and occupational therapy, until she headed back to Denton April 8.

Hallie has progressed nicely and is walking distances without support, Lewis said.

With further physical therapy and continued dedication she anticipates Hallie will be running, skipping and jumping in the future.

Hallies follow-up appointments at MD Anderson are scheduled every three months.

When Hallie was first diagnosed with osteosarcoma, she remembers telling her mother, God put me back in the hospital to help other children.

Now she advocates for both children with cancer and those with Diamond-Blackfan anemia.

At one point, while Hallie was healing from surgery, Elyse and Jesse went to a wall where donors names are displayed on the ninth floor of MD Anderson.

Every day, her dad and I passed the wall, Elsye said. One day, she wanted to see Hallie added to the names.

After changing the bylaws of the nonprofit, Hallies Heroes pledged $50,000 over five years in support of Lewis research in the area of pediatric sarcoma.

Hallie went on the wall in November.

It was really cool to come full circle with that, Elyse said. We were once there as parents, not knowing if our child would survive and seeing all the people donate money so that she could.

Now were giving back, because we want other children to survive, she added.

The funding will make a significant impact, Lewis said, and will go toward researching treatments for pediatric sarcoma.

Hallie is a success story, Lewis said. She is our ambassador and is a cheerleader to other patients. She wants to give back and help other kids like her.

Peyton is a Houston-based freelance writer.

Read the original post:
Surgery gives teen opportunity to help other kids with cancer - Houston Chronicle

Anadrole Reviews – Best Alternative to Anadrol Steroid? Any Side Effects? – MarylandReporter.com – MarylandReporter.com

Anadrole Reviews Does CrazyBulks Anadrole (Anadrol) Supplement Really Work? Do the ingredients have any negative side effects? Read its price, results, dosage & customer reviews!

Official Website: Click Here

What is Anadrole?

Anadrole is a muscle-building supplement developed by CrazyBulk that imitates the effects of the anabolic steroid Anadrol and androgen oxymetholone, which treat low levels of red blood cells.

Its primary function is to stimulate the synthesis of red blood cells in your body, which in turn helps to reduce the symptoms of anemia, including lethargy, muscle weakness, and weariness, among other symptoms.

Anadrole from CrazyBulk contains high concentrations of various proteins, amino acids, and ergogenic herbs.

These ingredients all work together to produce the same results as oxymetholone without harming your health.

It is designed to offer all of the advantages that its equivalent, available only by prescription, does, but without any potentially harmful effects.

Because the steroid Anadrol increases your stamina and assists you in fighting exhaustion, the Anadrole supplement makes it possible for you to attain bigger improvements in muscle mass.

It can effectively assist in growing muscle and bolstering muscle strength, and it speeds up the healing of muscles after exercise.

Your workouts will be more effective if you include them in your routine, and it is simple to use Anadrole in any fitness program.

Improve your physical performance, maintain your muscle mass, and shed excess weight with the help of this cutting-edge muscle-building supplement Anadrole.

It provides sustained energy surges, enabling you to work better and for longer at the gym. As a result, you can break through muscle-building plateaus more easily.

You will be able to achieve your fitness objectives more quickly and easily if you consistently apply this powerful method.

Click to Learn More About the Anadrole on the Official Website

How does Anadrole supplement work?

It accomplishes this by utilizing two metabolic processes stimulated by its proprietary formulas. To begin, taking this Anadrole can enhance a process known as erythropoiesis, which takes place in the bone marrow.

To put it another way, the stimulatory impact that the capsules have on the bone marrow stem cells causes an increase in the creation of red blood cells.

Because of this increased RBC, more oxygen will be carried into organs, particularly the muscles.

As a consequence, the muscles may be able to recover from weariness more quickly.

The second impact is known as the androgenic effect, which plays a role in both the manufacture of testosterone and the improvement of the bioavailability of male hormones.

Testosterone plays a significant role in the initiation of fat burning, which is beneficial to the process of creating lean muscle.

Click to Learn More About the Anadrole Supplement

Benefits of consuming Anadrole Capsules:

The Anadrole supplement sold by CrazyBulk is comprised of a potent composition that helps maintain your muscle health in a variety of ways.

Shocking New Anadrole Report: This May Change Your Mind

What are the Ingredients used in Anadrole Supplement?

Anadrole has appropriate quantities of natural substances that improve muscle strength, growth, and recovery and is packed full of these nutrients.

They cooperate to alleviate the symptoms associated with iron deficiency and low numbers of red blood cells.

In light of scientific research, the following is everything you need to know about the components that are found in Anadrole and the benefits that come from them:

Tribulus Terrestris, a plant native to the Mediterranean region that bears fruit and is a member of the caltrop family, is traditionally employed in herbal medicine as an aphrodisiac.

It is loaded with compounds that improve sexual performance in both men and women and has these substances in plenty.

The compounds found in the fruit of the Tribulus Terrestris plant have the power to interfere with the function of particular hormones in your body beneficially, which results in the production of ergogenic effects.

Anadrole from CrazyBulk has a total of 500 mg of Tribulus Terrestris fruit extract packed into every serving.

Soy protein is a type of protein that can be acquired from soybeans. It is unique in that it contains all of the essential amino acids your body cannot produce independently.

Because it is a complete protein, it stimulates muscle protein synthesis in your body by supplying your body with significant quantities of all of the required amino acids.

Losing weight, maintaining good cholesterol levels, and gaining muscle are all benefits. The Anadrole sold by CrazyBulk includes 200 mg of soy protein extract in every serving.

Whey protein, the primary protein found in dairy products, encourages the development of new proteins within your body by providing it with all of the needed amino acids.

It is a protein that is broken down very quickly and is an essential component in the process of creating new muscle protein.

Anadrole sold by CrazyBulk comes with 200 milligrams of whey protein concentrate in every single serving.

Nitric oxide can be produced from the amino acid L-arginine when it is metabolized in the body.

L-arginine has a role in maintaining healthy blood flow by contributing to the production of nitric oxide, which is important for keeping your blood vessels relaxed.

In addition, it influences particular hormones in your body, such as insulin and growth hormone, amongst others.

L-carnitine is a naturally occurring amino acid derivative that aids in synthesizing energy and enhances thermogenesis and encourages body fat reduction.

Your endurance will improve due to acetyl-l-role carnitine in the mitochondria, and you will be able to push yourself further during your workouts.

Acetyl l-carnitine is the primary factor responsible for Anadroles capacity to increase ones energy levels. Anadrole sold by CrazyBulk contains 50 mg of acetyl l-carnitine in every serving.

Shocking Results of This Anadrole Supplement Reported!

Pros of Anadrole:

Cons of Anadrole:

Check Out Anadrole Supplement Reviews From Real-Life Customers

Side effects of Anadrole Crazy Bulk

Anadrole does not contain an API, which stands for active pharmaceutical ingredient, or, to put it another way, the chemical compound responsible for carrying out all of the necessary functions.

The so-called beneficial effects are caused by certain herbs and the extracts of those herbs, similar to the way that Ayurvedic medications and other traditional treatments function.

Because you are genuinely consuming certain plant components in capsule form, there are no adverse consequences, unlike those caused by steroids, such as kidney failure, liver damage, high blood pressure, or organ damage.

Click to Order Anadrole Steroids From the Official Website (60 Days Money-Back Guarantee)

Pricing of Anadrole and Return Policy

One bottle of CrazyBulks Anadrole costs $64.99 and includes 60 individual capsules in each bottle.

If you buy two bottles at once, you will receive a free bottle as a bonus, and the total cost of 3 bottles is $129.98.

When you place an order straight through the official CrazyBulks Anadrole supplement website, you get free shipping on all of your purchases, no matter where you are.

Check Current Anadrole Supplement Pricing & Discounts!!

How to use Anadrole?

To experience the maximum potential of Anadrole, the manufacturer suggests taking two capsules each day for at least two months.

Because it requires the body a little bit more time to digest it, it is recommended that the Anadrole be taken first thing in the morning.

It is recommended that you take both capsules at the same time, at least twenty minutes before breakfast, to ensure that the Anadrole capsules are adequately absorbed along with the food.

When taking capsules, it is advisable to consume them with water or fruit juice; alcohol of any kind should be avoided at all costs.

The body is better able to properly distribute the tablets contents when it is given for 60 days consecutively followed by 10 days off cycle.

Click to Get the Best Deal on Anadrole from the Official Website

Anadrole Reviews Final Verdict

Anadrole is a great option for beginners and intermediates looking for a supplement that will help them gain muscle, increase their endurance and stamina, and improve their lean body mass.

This one, in contrast to other legal steroids, has a price tag that is slightly more reasonable, and its impact is comparable to that of the original steroid.

This products capacity to increase RBC counts assists in the fight against fatigue and shortens the time needed for recovery after exercise.

As a result of the herbal formulation, Crazy Bulk products do not cause any unfavorable health effects and do not cause any side effects.

Get Anadrole Now With Special Discount (Worldwide)!

Disclaimer: We are a professional product review website. We might receive compensation when you buy through our website, we may earn a small affiliate commission. The information contained on this website is provided for informational purposes only and is not meant to substitute for the advice provided by your doctor or other healthcare professional. The products have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease.

People also search for: anadrole reviews anadrole review anadrole crazy bulk review anadrole side effects anadrole crazy bulk anadrole vs anadrol anadrole crazy bulk side effects anadrole results anadrole ingredients

Continued here:
Anadrole Reviews - Best Alternative to Anadrol Steroid? Any Side Effects? - MarylandReporter.com - MarylandReporter.com

The gift of life: How stem cell transplant helped a flight attendant trump Cancer – The New Indian Express

Express News Service

CHENNAI: In 2004, flight attendant Kaveri Mandanna was battling frequent fevers, cold, and dipping haemoglobin. Life was an endless series of check-ups and blood transfusions. After consultations with a haematology specialist, tests and procedures ensued. Kaveri's condition was found to be leukaemia -- it meant that her bone marrow tissue was rapidly producing abnormal numbers of a certain type of blood cell, crowding out the others.

Although shaken, she didnt want to lose hope. "I had to be alive for my daughter -- that was the only thought pushing me to fight," says Kaveri who was in her 30s then.

A bone marrow transplant, also called a stem cell transplant, was recommended as a recourse. That gave Kaveri additional succour.

"Today, people suffering from rare diseases like certain types of cancer, sickle cell anaemia, immune conditions, and other conditions affecting the production of blood, have a shot at being cured through such stem cell transplants," says Dr G Buvaneswari, infertility specialist, Rela and GBR Hospitals.

Stem cells are special cells which can create copies of themselves. "These are the bodys raw cells -- they keep dividing and evolving into other cell types such as the bones, heart muscle, nerves, other organs and tissue," explains Dr Buvaneswari.

Its a matchThe tricky part of such transplants? Finding an immunologically compatible donor. As Kaveri had two siblings, who are natural genetic matches, they were HLA-typed.

Explaining this, Dr Buvaneswari says, "This procedure identifies protein markers on cells and tissues. The markers help determine whether or not a donor and a beneficiary match."

The more the markers, the fewer the risks of infection. To Kaveri's luck, her younger brother was found to be eligible to donate.

Uthappa, Kaveris brother and donor, was glad that he could potentially save his sister's life. However, he was apprehensive, too.

"Blood from one of my arms was collected every day, for five days, for a few hours. It was a smooth process, but, still, I was worried I'd experience side effects after giving away my stem cells," says Uthappa. But there was no cause for concern, he found, as donors are given injections to replicate extra bone marrow stem cells.

On D-day of the transplant process, Uthappa's stem cells were introduced into Kaveri's body via a catheter. Meanwhile, Kaveri had undergone chemotherapy which emptied her bone marrow of all its blood cells, including the healthy ones. This is done to make space for the donor's stem cells, says Dr Buvaneswari.

With time, the transplanted stem cells travelled to Kaveris bone marrow, where it started producing healthy red blood cells, white blood cells, and platelets of its own.

Kaveri still needed to do check-ups at regular intervals. "At first, I had to meet my specialists every week. Then, the frequency reduced to quarterly sessions, and later, once a year," Kaveri recounts. Subsequent signs of her cell count returning to the normal number indicated disease remission.

Almost six years later, from the day of the transplant in 2004, Kaveri's cancer was cured. "The transplant's success and the blessing of being declared cancer-free gave me the confidence to resume my globe-trotting life," she exclaims.

Banking for the futureWhile Kaveri was lucky enough to find a biologically-related donor, the odds in general are not quite high. Contacting a registry of voluntary unrelated donors is the only option then.Healthy individuals between the ages of 18 to 60 can register to donate their blood stem cells, says Sumati Misra, head, counselling and transplant centre management at DATRI blood stem cell registry. Having a wide pool of registered donors increases the odds of finding HLA matches for those needing transplants, she says.

"At DATRI, we have 1,800 patients registered with us who havent found a match yet from our registry of almost four lakh registered donors," shares Sumati.

Another factor in HLA typing is ethnicity, thus, it's hard to find a European registry match for an Indian. A large Indian donor registry solves that problem, she suggests.

Did you know that umbilical cord blood is a rich source of stem cells?

"The cord and the placenta, generally discarded as medical waste. They can be saved, and the stem cells from the tissue and the blood extracted, and stored for future transplant use," says Dr Buvaneswari.

As the blood is tested for infections, the likelihood of a person's body rejecting stem cells from cord blood is lesser than from bone marrow.

Some parents pay for their children's cord blood cells to be cryo-preserved in private banks for an extended period of time. They can be used in the rare event of a child developing a condition, in the future, that can be treated with stem cell therapy. The child's siblings stem cells, too, if they are HLA matches, can prove helpful.

"If the child is found to be an HLA match with another child, alternatively, parents can take a call on donating the banked cord blood. As cord blood banking is an expensive undertaking, donating them may be ideal," suggests Dr Buvaneswari.

Research on stem cells is underway to see if they can treat various conditions that affect different systems and parts of the body. Stem cell therapy could be a prospective game-changer in not just regenerating tissues but also organs, says Dr Buvaneswari, who is currently researching the use of stem cells in infertility treatment.

Sharing a recent trend from the field, the doctor says, "After pre-clinical trials with animals, it was observed that stem cell therapy could restore their ovarian and even testicular functions."

"After more phases of the trials with human cells, the results, if favourable, could lead to advancements in reproductive care," she concludes.

Follow this link:
The gift of life: How stem cell transplant helped a flight attendant trump Cancer - The New Indian Express

How Does Stem Cell Transplant Work In Thalassemia? Know Everything | TheHealthSite.com – TheHealthSite

Thalassemia is an inherited blood disorder that cannot be treated with medication. But stem cell therapy may be able to help. Know if stem cell therapy will work for the disease.

Written by Editorial Team | Updated : May 18, 2022 10:56 AM IST

Haemoglobin is the oxygen-carrying protein in the blood. In the absence or reduced amount of haemoglobin, the red cells do not survive for a long period and there is a diminished oxygen supply to the tissues causing a variety of symptoms. Thalassemia is an inherited blood disorder in which there is less haemoglobin than normal. There are two parts to the haemoglobin molecule alpha and beta. The disease is named based on the subunit that is not being made by the body alpha or beta-thalassemia.

Thalassemia runs in families; however, not everyone who has a dysfunctional gene for haemoglobin will have the symptoms of the disease. Those with moderate-severe disease experience symptoms such as breathlessness, weakness etc. (symptoms of anaemia), all associated with low levels of oxygen, from childhood. However, those with the mild disease might incidentally be diagnosed with thalassemia, mostly during investigations for other conditions or for anaemia.

Unfortunately, thalassemia cannot be prevented. Patients with the severe disease receive frequent blood transfusions, in an attempt to replenish a pool of healthy red blood cells. However, this procedure is associated with several issues such as iron overload that can deposit in different organs over time, immune system reactions, and risk of blood-related infections such as hepatitis, HIV etc. Folic acid is also prescribed to patients, which can help in the development of red blood cells.

Considering the issues with the conventional treatment of thalassemia, stem cell therapy can be an attractive choice for the condition. Allogeneic hematopoietic stem cell (blood stem cells) transplantation has been considered the only curative treatment for thalassemia. This treatment works by replenishing a healthy pool of blood-forming stem cells (master cells of the body) in the bone marrow consider the bone marrow as a factory of stem cells and specialized blood and tissue forming cells. However, considering that the source of stem cells is from a donor (usually a first-degree relative) because a patient's own blood-forming stem cells would be affected by the genetic mutation there are chances of certain side effects. One way to manage these issues is by the use of mesenchymal stem cells, which are known to have immune system regulating properties. By this, the rejection-related issues with hematopoietic stem cells as well as reduced immunity-related side effects can be handled efficiently. Considering that thalassemia is a disease that affects blood cells, mesenchymal cells (tissue forming cells) from the patient's own body are not affected.

Through this combined approach, a patient can achieve long-term remission from the symptoms of thalassemia without side effects. "Stem cell therapy for thalassemia is not a new treatment, only the approach by using a combination of stem cells to achieve holistic outcomes is novel.

(The article is contributed by Dr Pradeep Mahajan, Regenerative Medicine Researcher, StemRx Bioscience Solutions Pvt. Ltd., Navi Mumbai/Mumbai)

Follow us on

Link:
How Does Stem Cell Transplant Work In Thalassemia? Know Everything | TheHealthSite.com - TheHealthSite

What’s New in Equine Orthobiologics? The Horse – TheHorse.com

Named for their ability to branch out to become cells that build multiple kinds of tissue, mesenchymal stem cells (MSC) and mesenchymal stromal cells appear in embryos and adult bone marrow, respectively. In 2019 scientists suggested redefining the MSC acronym as medicinal signaling cells, because the therapeutic cells usually come from bone marrow rather than the mesenchymea part of embryos. In this article well refer to all these similar cell types as stem cells.

Twenty years ago biologists had successfully developed stem cells into cartilage, tendon, heart, bone, and other kinds of tissues in their laboratoriesspurring hope for unprecedented tissue repair therapies in humans and animals.

Scientists now know stem cells use a very different healing mechanism than previously suspected, Oosterlinck says. In fact, recent research has revealed its not what these cells become that matters, but what they doand, more specifically, how they do it, in large part through a process known as paracrine signaling.

Basically, theres a lot of crosstalk that happens between stem cells and the injured cells, Schnabel says. That crosstalk seems to recruit special cells within the injured tissue called progenitor cellsand those appear to develop into the original local tissue cells, such as tendon cells.

Some research groups are looking at ways to predifferentiate cells in a laboratorypreparing them to go into tendon versus cartilage tissue, for exampleto help encourage them to be more effective in their therapeutic environment, Oosterlinck says.

Meanwhile, other research teams are showing how stem cells trigger specific cytokines (cell-signaling proteins) and growth factors that contribute to better tissue healing, he says.

The cells also encourage vascularization, says Schnabel. They actually bring blood vessels into the area, promoting angiogenesis, she says.

These recent discoveries about stem cell functions are major breakthroughs, says Schnabel. Her team currently focuses on optimizing the use of these cells. One thing theyre homing in on is dosing, which has always been complex, especially in horses, because its impossible, she says, to achieve the per-pound dose of cells recommended in human medicine.

Theyre also fine-tuning the question of treatment timing, she says. Traditionally, clinicians have treated horses with stem cells once the initial inflammatory response from the injury subsides. The idea was that you dont want to cause more inflammation, potentially, and have an even lamer horse, and you dont want the stem cells to get killed by the inflammation, she explains.

Ultimately, that might not be the right approach. All the studies weve been doing actually suggest the opposite, that having them in an inflammatory environment is good, because it further primes the cells to secrete the things you want, she says.

Then that also begs the question, if you get a horse after the time of acute inflammation, could you prime the cells first in the lab so that theyre ready to go when you put them in the horse? she adds. And thats been a major focus of our work. We have a lot of strong preliminary data suggesting that thats true.

Schnabels team, as well as other research groups, have looked specifically at tendon healing, revealing that horses treated with stem cells have significantly reduced re-injury rates, especially in the superficial digital flexor tendon (SDFT)which has a traditional re-injury rate of up to 70% in racehorses (RK Smith, et al.). This is huge, she says.

See more here:
What's New in Equine Orthobiologics? The Horse - TheHorse.com

Cell Therapy Market Status and Size Report 2030 The Daily Vale – The Daily Vale

Theglobal cell therapy marketsize was valued atUSD 8.1 billion in 2021and is estimated to reachUSD 23.9 billion by 2030, growing at a CAGR of 14.5% over the forecast period. The development of precision medicine and advancements in cellular therapies in context to their efficiency & manufacturing are expected to be major drivers for the market. Moreover, the development of stem cell banking facilities and resultant enhancement of stem cells production, storage, and characterization are also expected to improve the volumetric capabilities of the market at a global level, which is anticipated to directly translate into revenue for this market at a larger level. Ongoing technological advancements in the parent and ancillary markets for stem and non-stem cells usage are expected to reinforce the demand over the forecast period. There are fewer commercialized cellular therapy products in the current market than the number of research products. This is partly due to stringent regulations and the high cost of stem cells.

Cell lines, such as Induced Pluripotent Stem Cells (iPSC) and human Embryonic Stem Cells (hESC) are recognized as having high growth potential; as a result, many research entities and companies are making significant investments in R&D pertaining to iPSC- and hESC-derived products.

Pricing of stem cell transplantation varies from region to region. For instance, the cost of transplantation in the U.S. is higher than that in Germany or China. In March 2018, Alofisel by TiGenix received approval for marketing in Europe. This was the first allogeneic stem cell therapy to be approved in Europe. Furthermore, revenue for certain products varies for the country; for instance, products like INVOSSA received approval for marketing in Korea but have yet to receive marketing authorization in the U.S. Growth is also influenced by the commercialization of unauthorized stem cell treatments revenue generation.

Get PDF for more Professional and Technical insights:https://www.marketstatsville.com/request-sample/cell-therapy-market

Global Cell Therapy Market Definition

Therapy in which viable cells are injected, grafted, or implanted into a patient to effectuate a medicinal effect is known ascell therapy; for instance, In immunotherapy, T-cells capable of fighting cancer cells via cell-mediated immunity are transplanted, and stem cells are grafted to regenerate diseased tissues.

Cellular therapies hold a great therapeutic promise across various clinical applications. This has resulted in substantial global investments in research and their clinical translation. Rapid advances in stem cell research have the potential to fulfill the unmet demand of pharmaceutical entities, biotech entities, and doctors in disease management. Several unknown therapies are in clinical development.

Furthermore, government and private funding agencies are constantly offering grants to support projects at various stages of clinical trials, increasing the number of ongoing clinical trials.

Research on human embryonic stem cells is ethically controversial. Harvesting embryonic stem cells involves the destruction of human embryos, raising a moral concern. In addition, stringent regulations for obtaining Intellectual Property Rights (IPR) for products or materials used in research are major restraints for commercializing these services. Ethical approval should be obtained to store cell lines and tissues in biorepositories to avoid the usage of tissue for illegal purposes or to identify proxy diseases to claim insurance. Moreover, controversies surrounding the use of embryonic stem cells for research impede the market growth in several regions

You Can Purchase Complete[emailprotected]https://www.marketstatsville.com/buy-now/cell-therapy-market?opt=2950

The study categorizes the cell therapy market based on use type and therapy type at the regional and global levels.

The analysis of the cell therapy market is based on the use of stem cells for clinical and research purposes. The research-use segment dominated the market for the global cell therapy market and accounted for the largest revenue share of 58.3% in 2021. Currently, cell therapies (stem & non-stem cells) are majorly being used for research projects, which in turn, has led to a large revenue share of this segment in 2021. Cell-based therapies are all possibilities for the replacement, repair, restoration, and regeneration of damaged tissues, cells, and organs. As an alternative to traditional treatment strategies, researchers are investing heavily in developing effective and safe cell-based treatments.

Access full Report Description,TOC, Table of Figure, Chart, etc.@https://www.marketstatsville.com/table-of-content/cell-therapy-market

As per the CGT Catapult database of clinical trials, 59 cell and gene therapy trials are ongoing in the UK. Out of all therapeutic areas, oncology has the highest number of ongoing clinical trials. T cells, CD34+ and CD133+ stem cells, mesenchymal stem/stromal cells are some predominantly employed cell types for clinical investigation. Neural cells, bone marrow mononuclear cells, fibroblasts, cornea cells, antigen-presenting cells, epithelial cells, and chondrocytes are some other cells that are being explored for the development of cell therapies.

Asia Pacificaccounts for the highestCAGR during the forecast period

Based on the regions, the global cell therapy market has been segmented across North America, AsiaPacific, Europe, South America, and the Middle East & Africa.In the Asia Pacific, the market for cell therapy is anticipated to witness a lucrative growth rate of 15.5% over the forecast period. Advancements in stem cell therapy in Asian countries are observed to be better than those in the U.S. This has resulted in Asia leading stem cell research. Several stem cell consortiums in Asian countries aim to ensure coordinated and focused R&D programs. Moreover, patients from western countries migrate to Asian countries for treatment, owing to the flexible legal framework.

Companies from Japan, South Korea, India, China, Taiwan, Singapore, and the rest of Asia were active participants in the conference. In addition, the large regional population and untapped potential present in the region have resulted in global firms entering the market. Moreover, this region offers relatively inexpensive manufacturing & operating units for conducting research. These factors are expected to play a major role in expanding the stem cell market in this region.

Request For Report Description @https://www.marketstatsville.com/cell-therapy-market

The cell therapy market is mildly concentrated in nature with few numbers of global players operating in the market such as Kolon TissueGene, Inc., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., Castle Creek Biosciences, Inc., MEDIPOST, Osiris Therapeutics, Inc., PHARMICELL Co., Ltd, Tameika Cell Technologies, Inc., Cells for Cells, NuVasive, Inc., Vericel Corporation, and Celgene Corporation

Read the original here:
Cell Therapy Market Status and Size Report 2030 The Daily Vale - The Daily Vale

Personalized Cell Therapy Market 2022 Strategic Analysis, Growth Drivers, Industry Trends, Demand and Future Opportunities till 2028 |Novartis AG,…

personalized-cell-therapy-market

Global Personalized Cell Therapy Market is growing at a High CAGR during the forecast period 2022-2028. The increasing interest of the individuals in this industry is that the major reason for the expansion of this market and This has brought along several changes in This report also covers the impact ofCOVID-19on the global market.

The latest research report, titled Personalized Cell TherapyMarket Added by Market Info Reports, provides the reader with a comprehensive overview of the Personalized Cell Therapy Industry and familiarizes them with the latest market trends, industry information, and market share. The report content includes technology, industry drivers, geographic trends, market statistics, market forecasts, producers, and raw material/equipment suppliers. Global Personalized Cell Therapy market size was xx million US$ and it is expected to reach xx million US$ by the end of 2028, with a CAGR of XX between 2022 and 2028.

Personalized Cell Therapy Market competition by top manufacturers as follow:Novartis AG, Vericel Corporation, Bellicum Pharmaceuticals, MolMed SpA, Cytori Therapeutics Inc, Gilead Sciences, Inc, Celgene Corporation, Bluebird Bio, Aurora Biopharma Inc, Saneron CCEL Therapeutics?Inc, Kuur Therapeutics, MediGene AG, Sangamo Therapeutics and More

Get Sample PDF including COVID19 Impact Analysis, full TOC, Tables and [emailprotected]https://www.marketinforeports.com/Market-Reports/Request-Sample/480529

Dont miss the trading opportunities on Personalized Cell Therapy Market. Talk to our analyst and gain key industry insights that will help your business grow as you create PDF sample reports.

The global Personalized Cell Therapy market has been segmented on the basis of technology, product type, application, distribution channel, end-user, and industry vertical, along with the geography, delivering valuable insights.

Market split by Type, can be divided into:By Cell TypeHematopoietic Stem CellSkeletal Muscle Stem Cell/Mesenchymal Stem Cells/LymphocytesBy TechniquePlatelet Transfusions/Bone Marrow Transplantation/Packed Red Cell Transfusions/Organ Transplantation

Market split by Application, can be divided into:Cardiovascular DiseasesNeurological DisordersInflammatory DiseasesDiabetesCancer

Share your budget and Get Exclusive Discount @https://www.marketinforeports.com/Market-Reports/Request_discount/480529

Market segment by Regions/Countries, this report covers:North AmericaEuropeChinaRest of Asia PacificCentral & South AmericaMiddle East & Africa

Years Considered to Estimate the Market Size:History Year: 2015-2019Base Year: 2019Estimated Year: 2022Forecast Year: 2022-2028

Major factors covered in the report:

Detailed TOC of Personalized Cell Therapy Market Report 2022-2028:Chapter 1: Personalized Cell Therapy Market OverviewChapter 2: Economic Impact on IndustryChapter 3: Market Competition by ManufacturersChapter 4: Production, Revenue (Value) by RegionChapter 5: Supply (Production), Consumption, Export, Import by RegionsChapter 6: Production, Revenue (Value), Price Trend by TypeChapter 7: Market Analysis by ApplicationChapter 8: Manufacturing Cost AnalysisChapter 9: Industrial Chain, Sourcing Strategy and Downstream BuyersChapter 10: Marketing Strategy Analysis, Distributors/TradersChapter 11: Market Effect Factors AnalysisChapter 12: Personalized Cell Therapy Market ForecastContinued

Access full Report Description, TOC, Table of Figure, Chart, etc.@ https://www.marketinforeports.com/Market-Reports/480529/personalized-cell-therapy-market

The analysis objectives of the report are:

Does this report provide customization?Customization helps organizations gain insight into specific market segments and areas of interest. Therefore, Market Info Reports provides customized report information according to business needs for strategic calls.

Get Customization of the [emailprotected]:https://www.marketinforeports.com/Market-Reports/Request-Customization/480529/personalized-cell-therapy-market

Why Choose Market Info Reports?:Market Info Reports Research delivers strategic market research reports, industry analysis, statistical surveys and forecast data on products and services, markets and companies. Our clientele ranges mix of global business leaders, government organizations, SMEs, individuals and Start-ups, top management consulting firms, universities, etc. Our library of 600,000 + reports targets high growth emerging markets in the USA, Europe Middle East, Africa, Asia Pacific covering industries like IT, Telecom, Chemical, Semiconductor, Healthcare, Pharmaceutical, Energy and Power, Manufacturing, Automotive and Transportation, Food and Beverages, etc. This large collection of insightful reports assists clients to stay ahead of time and competition. We help in business decision-making on aspects such as market entry strategies, market sizing, market share analysis, sales and revenue, technology trends, competitive analysis, product portfolio, and application analysis, etc.

Contact Us:Market Info Reports17224 S. Figueroa Street,Gardena, California (CA) 90248, United StatesCall: +1 915 229 3004 (U.S)+44 7452 242832 (U.K)Website: http://www.marketinforeports.com

Excerpt from:
Personalized Cell Therapy Market 2022 Strategic Analysis, Growth Drivers, Industry Trends, Demand and Future Opportunities till 2028 |Novartis AG,...

Archives